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ABSTRACT 
 
The CLCA gene family produces both secreted and membrane-associated proteins that modulate 
ion-channel activity, drive mucus production and have a poorly understood pleiotropic effect on 
airway inflammation. The mechanism of how hCLCA1 regulates airway inflammation remains 
unknown. However, hCLCA1 induction in inflamed airway epithelium is higher than most 
cytokines and chemokines that activate resident and recruited macrophages’ innate immune 
response. Thus, it is possible that hCLCA1’s role in airway inflammation is to regulate the 
immune response of macrophages. Here, we demonstrated the ability of secreted hCLCA1 to 
activate macrophages, inducing them to express pro-inflammatory cytokines and to undertake a 
pivotal role in airway inflammation.  The VWA domain within hCLCA1 was found to be 
responsible for the activation, which correlated with induction of the NF-κB and MAPK 
pathways. These findings open a new area of investigation into the function of CLCA proteins 
and should be of therapeutic interest. 
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INTRODUCTION 
 
1.1 Rationale 
 
Inflamed airway diseases such as asthma, cystic fibrosis, and chronic obstructive pulmonary 
disease affect one in seven people in North America. The hallmarks of these inflamed airway 
diseases include goblet cell hyperplasia, mucus hypersecretion and airway inflammation. If 
inflammation is not resolved, it could lead to airway remodeling, mucus hypersecretion, and 
tissue destruction. The consequences of these pathological conditions will lead to bacterial 
infection, chronic bronchitis, airflow obstruction, etc.  
During airway inflammation, epithelial cells secrete high levels of pro-inflammatory cytokines 
and hCLCA1. The pro-inflammatory cytokines stimulate resident alveolar macrophages to 
release chemokines. The chemokines then recruit more macrophages to the site of inflammation 
and even more pro-inflammatory cytokines are released, and the inflammation is amplified. 
hCLCA1, a gene belong to the CLCA gene family, has well-documented pleiotropic effects in 
mucus regulation and ion channel modulation. However, the mechanism by which hCLCA1 
exerts its effect remains unknown. 
Since hCLCA1 proteins are secreted in the same proximity as the macrophages during airway 
inflammation, we hypothesize that hCLCA1 also has the ability to regulate the immune response 
in macrophages. Macrophages are one of the most important immune cells in humans. They have 
multiple functions including initiation of inflammatory response, resolution of inflammation, and 
tissue repair. Interaction of hCLCA1 and macrophages might explain how hCLCA1 is 
responsible for many different physiological functions. 
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1.2 Objectives 
 
1. To determine if secreted hCLCA1 could act as a signaling molecule to induce 
cytokine expression in macrophages 
 
2. To determine the functional domain of hCLCA1 and the signal transduction pathway 
that is involved in macrophage activation 
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1.3 Hypotheses 
 
1. Secreted hCLCA1 activates and induces pro-inflammatory cytokine expression in 
macrophages 
 
2. Von Willebrand Factor Type A (VWA) domain within hCLCA1 is responsible for up-
regulating cytokine expression in macrophages  
 
3. Mitogen-activated protein kinase (MAPK) or nuclear factor-kappa B (NF-κB) 
signaling pathways are involved with hCLCA1’s VWA domain stimulation 
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LITERATURE REVIEW 
 
2.1 Calcium-activated chloride channel (CLCA) proteins 
 
2.1.1 Backgrounds 
 
The CLCA genes (CL stands for chloride-channel modulating and CA for calcium-activated) were 
initially identified as the pore subunits of a calcium-activated chloride channel1. They were 
subsequently renamed to be chloride channel accessory proteins due to accumulating 
experimental data and advancement in bioinformatics. Of all the CLCA genes, human hCLCA1 
and its murine ortholog mCLCA3 have been the most extensively studied. The gene products 
have pleiotropic effects, generating secreted and membrane-associated proteins that increase 
mucus production, airway responsiveness, and increase calcium-activated chloride channel 
conductance. They are also highly expressed in the airway epithelium in inflammatory airway 
diseases such as cystic fibrosis, asthma, and chronic obstructive pulmonary disease. However, it 
is still unclear how hCLCA1 or mCLCA3 can exert such pleiotropic effects. 
 
2.1.1.1  Initial model of CLCA proteins 
 
The initial member of the CLCA family was identified through immuno-precipitation using an 
antibody against a 38 kDa protein (anti-P38) in bovine tracheal epithelium in 19922. The proteins 
immuno-purified using the antibody yielded products of varying molecular weights, 38, 62-64 
and 140 kDa. The author concluded that the varying molecular weight proteins were monomeric, 
dimeric and tetrameric forms of the same product. It was suggested that the 140 kDa protein 
constituted the functional channel by linking four identical 38 kDa subunits through disulfide 
bonds. When reconstituted into lipid bilayers, the protein gave rise to anion conductance with an 
I- > Cl- selectivity, and it was sensitive to the chloride channel blocker DIDS. Consistent with the 
channel being linked by disulfide-bonds, the channel activity was abolished when it was treated 
with dithiothreitol (DTT).  Similarly, a protein involved in conductive chloride transport was also 
discovered in porcine ileal brush-border membrane in 19913, this protein was later cloned and 
identified as pCLCA1 in 20004.  
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The first clone of hCLCA1 was being reported in 1995. By using the anti-P38 antibody 
mentioned above, Cunningham et al. cloned a cDNA thought to encode the putative chloride 
channel expressed in epithelial cells in bovine trachea1. The cloned cDNA encoded for a 903 
amino acid long protein, and it was believed to be a Ca2+/calmodulin-dependent protein kinase-
regulated chloride channel. This protein was predicted to have a membrane protein structure with 
at least four transmembrane-spanning regions. When expressed in Xenopus oocytes, the protein 
displayed outwardly rectified current that was anion-selective. The current was increased 
following exposure to calcium ionophore and inhibited by channel inhibitors. The authors 
concluded that the protein encoded a calcium-activated chloride channel (CaCC) and the current 
was similar to the electrophysiological characteristics of previous detected CaCC. This protein 
was subsequently named bCLCA1.  
 
Over the next few years, several members of this gene family were cloned and identified from 
different mammalian species using gene screening (human, mouse, bovine)4-12, and they were 
found to function as CaCCs as well. This was supported by electrophysiological experiments in 
which heterologous expression of CLCA isoforms from various species (human, mouse, bovine, 
pig) in HEK293 or NIH/3T3 cells increased chloride currents in response to increasing calcium in 
the cytosol13-15.  
 
2.1.1.2  Current and evolving model of CLCA proteins 
 
However, there were inconsistencies to the initial model that had suggested CLCA proteins were 
CaCCs themselves. Structurally, the predicted transmembrane-spanning regions for some of the 
CLCAs included a soluble von Willebrand factor type A (VWA) domain, which was inconsistent 
with being a channel6. Typically, amino acids in the transmembrane-spanning regions of an ion 
channel are organized into alpha-helix or beta-barrel structure. Functionally, members of the 
CLCA family were linked to roles other than ion channels, playing a role in regulation of mucus 
production (mCLCA3) and tumor suppression (CLCA2)16, 17. Moreover, some of the CLCA 
proteins were reported to be cell adhesion molecules (e.g. hCLCA2) or to be truncated with no 
transmembrane-spanning regions (hCLCA3), thus they could not form the chloride channels 
themselves18.  
	 6	
The accumulating experimental results and advancement in bioinformatics led to a new model for 
CLCA structures and functions. The current model described CLCA proteins as soluble secreted 
molecules with the exception of a subset of CLCA proteins that contain a C-terminal membrane 
anchoring region19, 20. A common feature shared by the CLCA family of proteins is the presence 
of a proteolytic cleavage site near the C-terminus, and all the CLCA isoforms tested in 
mammalian cell culture system seemed to be processed similarly5, 19-26. Generally, a precursor 
~120 kDa glycoprotein is cleaved into two products: a ~85 kDa N-terminal subunit and a ~35 
kDa C-terminal subunit. However, the size of the proteins seems to be cell-line- and tissue-
dependent17. All N-terminal subunits are secreted into the extracellular space while the C-
terminal subunits are either secreted or retained inside the cells depending on the CLCA 
ortholog20-23. Today, CLCA genes have been renamed to chloride channel accessory proteins. 
Although CLCA family proteins do not form the pore subunits of the CaCCs, they remain 
important to many physiological functions including regulation of chloride channel conductance, 
modulation of mucus expression, regulation of immune responses, etc (Table 2.1). To date, 
CLCA genes from other mammalian species have been identified, and this has allowed the 
categorization of CLCA from different species into different subgroups based on the level of 
sequence similarity (Table 2.2, Figure 2.1 and 2.2).  
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Table 2.1. Tissue expressions and functions of mammalian CLCA gene homologs. 
 
Gene Tissue Distribution Functions 
hCLCA1 Airway mucous cells, intestinal 
goblet cells, uterus, stomach, testis, 
kidney 
Increases CaCC conductance, 
induces goblet cell metaplasia, 
regulates airway inflammation 
hCLCA2 Lung, trachea, mammary gland, 
testis, prostate, bladder, stomach 
Increases CaCC conductance, 
tumor promoter and suppressor 
hCLCA3 Lung, trachea, mammary gland, 
thymus, spleen 
No function reported 
hCLCA4 Colon, bladder, uterus, trachea, 
stomach, prostate, mammary gland, 
brain 
Possible disease modifier for cystic 
fibrosis 
mCLCA1 Lung, aorta, spleen, bone marrow, 
lymph nodes, brain, kidney, skin, 
liver, spleen, intestine, cecum, dorsal 
root ganglion, breast 
Increases CaCC conductance, 
tumor promoter and suppressor 
mCLCA2 Involuted mammary tissues, thymus, 
colon, intestine, bladder, epididymis, 
vesicular gland, skin, dorsal root 
ganglion 
Tumor suppressor, possible 
apoptotic inducer 
mCLCA3 Mucous cells of small intestines, 
colon, lung, trachea, uterus, stomach 
Induces goblet cell metaplasia, 
possible inducer for airway hyper-
responsiveness, induces airway 
inflammation 
mCLCA4 Smooth muscle of lung, heart, uterus, 
bladder, stomach, aorta, skeletal 
muscle, intestinal goblet cells 
Increases CaCC conductance that 
mimics native chloride 
conductance in smooth muscle 
mCLCA5 Eye, spleen, heart, intestine, lung, 
skeletal muscle, stomach, testis, 
dorsal root ganglion 
Increases CaCC conductance, 
induces goblet cell metaplasia, 
tumor suppressor 
mCLCA6 Intestine, stomach Increases CaCC conductance, 
potential regulator for CFTR 
mCLCA7 No expression reported No function reported 
mCLCA8 No expression reported No function reported 
pCLCA1 Surface epithelium in ileum, surface 
epithelium and submucosal glands in 
trachea, sublingual, submandibular 
and parotid salivary glands 
Increases CaCC conductance, 
increases cAMP-dependent 
chloride conductance 
pCLCA2 Skin Potential role in structural integrity 
of the skin 
pCLCA4 Lung No function reported 
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Table 2.2. Human CLCAs and their animal homologs. h = human, m = murine, p = porcine, b 
= bovine, e = equine. 
 
Human CLCAs hCLCA1 hCLCA2 hCLCA3 hCLCA4 
 
Animal homologs 
mCLCA3 
pCLCA1 
bCLCA1 
eCLCA1 
mCLCA5 
pCLCA2 
bCLCA2 
eCLCA2 
mCLCA1 
mCLCA2 
mCLCA4 
bCLCA3 
 
mCLCA6 
mCLCA7 
mCLCA8 
pCLCA4 
bCLCA4 
eCLCA4 
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Figure 2.1. Phylogenetic tree for CLCA family members in human, mouse, pig, horse, and 
cow. The analysis was performed on the Phylogeny.fr platform. Sequences were aligned with 
MUSCLE (v3.8.31), the phylogenetic tree was reconstructed using PhyML program (v3.1/3.0 
aLRT), and the graphical representation was generated with TreeDyn (v198.3)27-33. The bar 
represents 20% sequence diversity. Each color represents a homologous group comparing to each 
human CLCA gene.  
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Figure 2.2. Annotated sequence alignment for CLCA proteins in human, mouse, and pig. 
Sequence analysis and alignment were performed with T-Coffee multiple sequence alignment 
program. The color indicates the levels of similarity between different CLCA homologs, with 
purple being the least similar to pink being the most similar. The domains (hydrolase domain, 
VWA domain, and FN3 domain) are identified based on hCLCA1 sequence. The blue arrows 
indicate the sites of metal-ion-dependent adhesion site (MIDAS) motifs. The blue boxes indicate 
the location of hydrolase active site motif or β4-intergrin motif. Sequence conversation is denoted 
by consensus symbols: an asterisk (*) indicates positions which have a single, fully conserved 
residue, a colon (:) indicates conservation between groups of strongly similar properties, and 
period (.) indicates conservation between groups of weakly similar properties. 
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2.1.1.3  CLCA homologs in mammalian species 
 
To date, CLCA homologs have been identified in many species (human, mouse, pig, horse, etc.). 
This section will cover the tissue distributions as well as the functions of different CLCAs 
expressed in human, mouse, and pig. There are 4 identified CLCAs in human, 6 or more in 
mouse, and 3 in pig.  
 
2.1.1.3.1 Human CLCAs 
 
The first human CLCA gene identified was hCLCA1 and it is the most extensively studied 
human CLCA gene6. It is expressed in multiple tissues, predominantly in the mucus-secreting 
cells in the airways and small and large intestines5, 34, with much lower expression levels in the 
uterus, stomach, testis, and kidney35. Transient expression of hCLCA1 in HEK293 cell line 
increased calcium-activated chloride channel (CaCC) conductance6, 36. Recently, a study 
demonstrated hCLCA1’s ability to increase CaCC conductance by increasing the surface 
expression of endogenous transmembrane member 16A (TMEM16A), the actual calcium-
activated chloride channel37. hCLCA1 has also been intensely studied with its association with 
mucus production. Experimental results demonstrated that transient expression of hCLCA1 in 
vitro could induce mucus production38-40, and hCLCA1 was reported to be significantly induced 
in the airway epithelia of patients suffering from airway diseases such as cystic fibrosis (CF), 
asthma, and chronic obstructive pulmonary disease (COPD) (See section 2.2; Respiratory 
diseases)34, 41-44. To add another layer of complexity to the functions of hCLCA1, we were the 
first ones to demonstrate that secreted hCLCA1 could act as a signaling molecule and induce pro-
inflammatory cytokine expression in macrophages, suggesting its role in immune regulation45. 
We were also the first to show that the secreted form of hCLCA1 possesses physiological 
functions. This signaling property of hCLCA1 might explain how hCLCA1 can have such a 
pleiotropic effect toward different physiological functions. 
 
The second member of the hCLCA family, hCLCA2, is expressed in the lung, trachea and 
mammary gland12, with weak expression in testis, prostate, bladder and stomach35. Similar to 
hCLCA1, transient expression of hCLCA2 in HEK293 also increased CaCC conductance12. 
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Interestingly, hCLCA2 seems to play a role in both tumor metastasis and suppression. One study 
demonstrated that the β4-binding motif in the VWA domain of hCLCA2 could bind to the β4 
integrin expressed on breast cancer cells, and this led to metastatic spread of the cancer16. 
However, β4-integrin motif is only present in hCLCA2, mCLCA1, and mCLCA2 (Figure 2.2). 
Contrary to the tumor metastatic role, hCLCA2 also seems to partake a role in tumor suppression. 
Gruber and Pauli found that hCLCA2, which expressed abundantly in normal breast epithelial 
cells, was depleted in transformed tumorigenic cell lines18. In addition, when the highly 
metastatic breast cancer cell line transgenically expressing hCLCA2 was injected into nude mice, 
it decreased the capacity of these cells for invasion and tumor generation18.  
 
Unlike other CLCA homologs, hCLCA3 is a truncated CLCA protein with a premature stop 
codon, and the expressed protein is secreted into the medium in vitro9. It was reported to express 
in the lung, trachea, mammary gland, thymus and spleen9. However, no function has been 
reported for hCLCA3. The fourth member of human CLCA, hCLCA4, is expressed in various 
tissues including the colon, bladder, uterus, trachea, stomach, prostate, mammary gland, and it is 
the only human CLCA that expresses in the brain35. However, the function of hCLCA4 remains 
unknown, although it was suggested to be a potential modifier of disease severity in cystic 
fibrosis46.  
 
2.1.1.3.2 Mouse CLCAs 
 
mCLCA1 was the first identified murine CLCA gene, and it was found to express in a variety of 
tissues including the lung, aorta, spleen, bone marrow, lymph nodes, brain, kidney, skin, liver, 
spleen, intestine, cecum, brain, dorsal root ganglion and breast11, 18, 47, 48. Similar to other CLCA 
orthologs, expression of mCLCA1 in HEK293 or Xenopus oocytes increased CaCC currents5, 11. 
Like hCLCA2, mCLCA1 seems to partake in both tumor promotion and suppression. One study 
showed that the binding of mCLCA1 and β4-intergrin expressed on mouse skin melanoma cell 
line activated focal adhesion kinase (FAK), which activated downstream extracellular signal 
regulated kinase (ERK) and promoted proliferation of tumor cells (see section 2.3.3.2; 
MAPKs)49. In addition, this study found that the FAK-mediated signaling to ERK is Src-
dependent. The mCLCA1-β4-intergrin interaction promoted FAK autophosphorylation at 
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Tyr397, which created a binding site for Src. Interaction with Src further phosphorylated FAK, 
creating an SH2-binding site for growth factor receptor-bound protein 2 (Grb2), which 
subsequently activated the downstream signaling to ERK. It is important to note that Grb2 is also 
an intermediate adaptor protein that can activate downstream p38 mitogen-activated protein 
kinases (p38). However, the author did not investigate p38 activation likely because ERK is 
involved in cell proliferation while p38 is involved in inflammation. This study looked at three 
different signaling targets that were immediately downstream of focal adhesions: focal adhesion 
kinase (FAK), proline-rich tyrosine kinase-2 (Pyk2), and phosphatidylinositol 3-kinase (PI3K). 
However, only FAK was strongly activated upon mCLCA1 interaction. It is important to note 
that activation of PI3K subsequently phosphorylates serine/threonine kinase Akt, and 
phosphorylated Akt phosphorylates IKKα, resulting in activation of nuclear factor-kappa B (NF-
κB) pathway (See Section 2.3.3.1; Nuclear factor-kappa B)50. Although mCLCA1-β4-integrin 
interaction did not promote PI3K activation, it does not exclude the possibility that the β4-
binding motif in other CLCAs could activate PI3K pathway that will eventually lead to NF-κB 
activation. Contrary to the above study, another study reported that mCLCA1 was down-
regulated in human breast cancer cell line51. When mCLCA1 was reintroduced into the tumor cell 
line by transfection, reduced growth rate and survival rate was observed51. These contrary results 
suggest that the effect of mCLCA1 on tumor cell growth might be cell-line or species-dependent.  
 
The second member of the murine CLCA family, mCLCA2, is an ortholog of mCLCA1 that 
expresses in low levels in most of the tissues48. Strong expression of mCLCA2 was observed in 
involuted mammary tissues, but not in pregnant or lactating tissues48, 52. With the highest 
expression found in cells with high turnover, mCLCA2 was suggested to have an apoptotic role 
in these tissues. Indeed, further experiment indicated that mCLCA2 expression was induced in 
response to apoptotic stimuli51. When mCLCA2 was transfected into tumor cell line, it elicited a 
survival inhibitory effect which was more potent than that induced by mCLCA151.  
 
mCLCA3, also known as gob-5, is a murine ortholog of hCLCA1 and is the most well-studied 
CLCA gene in mouse. It expresses in the mucous cells of different tissues including small 
intestine, colon, lung, trachea, uterus and stomach, with the highest expression in gastrointestinal 
and respiratory tracts10, 17. Although expression of mCLCA3 in vitro generated CaCC 
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conductance, the effect cannot be reproduced in vivo with mCLCA3 knockout mice53. This could 
be attributed to the redundancy of CLCAs in mice, in which other CLCAs compensate for the 
loss of mCLCA3. However, most of the attention of mCLCA3 was focused in its association with 
mucus production. Similar to its human ortholog hCLCA1, transient expression of mCLCA3 in 
vitro caused significant increase in mucus production43. It was reported that mCLCA3 expression 
was selectively induced in asthmatic mice, and administration of adenovirus-expressing antisense 
mCLCA3 inhibited the development of goblet cell metaplasia and airway hyper-responsiveness 
while overexpression of mCLCA3 exacerbated the asthma phenotype43. This was partly 
consistent with a study that demonstrated mCLCA3 gene transfer induced goblet cell metaplasia 
but not airway hyper-responsiveness54. These results were supported by a recent study that 
intranasal administration of mCLCA3 antibody significantly reduced airway inflammation, 
goblet cell hyperplasia and mCLCA3 expression in asthmatic mice55.  
 
The fourth member of the murine CLCA, mCLCA4, is expressed in smooth muscle of uterus, 
lung, heart, bladder, stomach, aorta, skeletal muscle and in the mucous cell in gastrointestinal 
tracts26. Expression of mCLCA4 in HEK293 exhibited CaCC conductance that mimicked the 
native calcium-activated chloride channels in smooth muscles26. However, no other physiological 
functions of mCLCA4 have been reported. One study showed that the luminal sorting motifs on 
mCLCA4 sequence was required for export from endoplasmic reticulum and subsequent 
proteolytic processing. The same study demonstrated that mutation in the luminal sorting motifs 
cause mCLCA4 to be trapped in the endoplasmic reticulum and have impaired proteolytic 
cleavage of itself22. It is likely that other CLCAs are processed in a similar manner since most 
CLCAs have high sequence homologies at their N-terminal (Figure 2.2).  
 
mCLCA5 is a murine ortholog of hCLCA2. Similar to hCLCA2, mCLCA5 is expressed in a 
variety of tissues including heart, intestine, lung, skeletal muscle, stomach, testis, dorsal root 
ganglion, and highest expression in spleen and eye47, 56. Like other CLCAs, transfection of 
mCLCA5 in HEK293 also generated CaCC current56. The expression of mCLCA5 was found to 
increase in mCLCA3 knockout mice experiencing goblet cell metaplasia. In addition, the author 
showed mCLCA5 gene transfer was sufficient to drive goblet cell metaplasia in mice54, 
suggesting mCLCA5 might compensate for the loss of mCLCA3 in mice. Similar to its human 
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ortholog hCLCA2, mCLCA5 expression was found to decrease in tumor cells while increase 
under serum-free conditions, suggesting its role as an apoptotic inducer. This was supported by 
the arrest of cell growth and colony formation after mCLCA5 was expressed in the tumor cell 
line24.  
 
mCLCA6, which is a murine ortholog of hCLCA4, expresses predominantly in intestine and 
stomach56. Expression of mCLCA6 also generated CaCC conductance56. One study reported that 
mCLCA6 colocalized with cystic fibrosis transmembrane regulator (CFTR) at the apical surface 
of colonic crypt cells. This suggested a direct or indirect role of mCLCA6 in transepithelial anion 
conductance in the mouse intestine19. Using BLAST program to search for homologs of the 
mCLCA3, Patel et al. discovered mCLCA7 and mCLCA8 gene. However, no expression and 
functional studies have been reported57. 
 
2.1.1.3.3 Pig CLCAs 
 
The first member of porcine CLCA family, pCLCA1, is an ortholog of hCLCA1 and mCLCA3. 
It expresses predominantly in the surface epithelium in ileum, surface epithelium and the 
underlying submucosal glands in the trachea, and low levels in sublingual, submandibular and 
parotid salivary glands4, 58. pCLCA1 was suggested to be a mediator for both CaCC and cyclic 
adenosine monophosphate (cAMP)-dependent chloride channel4, 59, 60. Increased calcium-
activated chloride conductance was observed when expressed in NIH/3T3 cells4. In addition, 
expression of pCLCA1 in an intestinal epithelial CaCO-2 cell line also induced cAMP-dependent 
chloride conductance, possibly through the regulation of CFTR59. The same group subsequently 
showed that the regulation of cAMP-dependent chloride channel by pCLCA1 persisted in mature 
polarized CaCO-2 cells, in which the calcium-activated chloride conductance disappeared60. 
 
The second member of the porcine CLCA family, pCLCA2, is an ortholog of human hCLCA2 
and murine mCLCA5 and is the only member of CLCA that expresses in the skin, and the author 
suggested that pCLCA2 might play a role in the structural integrity of the skin61.  
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The third member of the porcine CLCA gene, pCLCA4, is an ortholog of hCLCA4 and mCLCA6 
that expresses strongly in the lung62. However, similar to pCLCA2, no functional studies have 
been conducted on these genes.  
 
2.1.2 Protein structure of hCLCA1 
 
2.1.2.1  Molecular characteristics and functional domains 
 
The hCLCA1 gene is located on chromosome 1 (1p22.3) and encodes a 914 amino acid protein 
with a calculated molecular mass of 100.3 kDa. Using the ScanProsite bioinformatics tool, it is 
predicted that hCLCA1 contains 18 potential sites for N-myristoylation, 13 consensus sites for 
protein kinase C phosphorylation, 2 consensus sites for amidation, 12 consensus sites for casein 
kinase II phosphorylation, 3 consensus sites for Ca2+/calmodulin dependent kinase II 
phosphorylation, and 8 potential sites for asparagine-linked glycosylation14, 63. Post-translational 
modifications such as myristoylation and glycosylation could be vital to hCLCA1 signal 
transduction ability. Myristoylation allows weak protein-protein and protein-lipid interaction, and 
it has been shown to play an essential role in protein-protein interaction and signal transduction64. 
On the other hand, glycosylation is known to modulate the structure and function of signaling 
molecules65-67. Proteomic bioinformatics has indicated that hCLCA1 contains functional domains 
that are commonly shared among CLCA gene family5, 19-26. These specifically include domains 
such as hydrolase domain, von Willebrand Factor type A domain, and Fibronectin type III (FN3) 
domain (Figure 2.3).  
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Figure 2.3. Structural scheme of hCLCA1 protein. Using NCBI’s conserved domains 
database, three domains were predicted in hCLCA1. The hydrolase domain lies between 1-261 
residues at the N-terminal of the protein. The von Willebrand factor type A (VWA) domain is 
located between 305-458 residues, and the fibronectin type III (FN3) domain is located between 
753-816 residues of hCLCA1.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
	 25	
2.1.2.1.1 Hydrolase domain 
 
Recent studies have identified the presence of a hydrolase domain in the N-terminal region of the 
hCLCA1 protein (1-261 residues)68. The study reported that the structural prediction of the 
hydrolase domain was similar to that of the zinc-dependent metalloproteases with a His-Glu-x-x-
His (HExxH) active site motif, and the hydrolase function was abolished when glutamate residue 
157 was mutated into glutamine (HEWAH à HQWAH). A follow up study by the same group 
demonstrated that this HExxH motif is well-conserved in the CLCA family69.  
 
When hCLCA1 is expressed, it is subjected to glycosylation and possible myristoylation, 
increasing its molecular mass from ~100 kDa to ~130 kDa. Then the hydrolase domain 
autocleaves the precursor hCLCA1 into a ~90 kDa amino-terminal and ~40 kDa carboxyl-
terminal subunits. Although it was reported that both subunits were secreted into the extracellular 
compartment6, our results showed otherwise. From our western blot analysis, we found that only 
the glycosylated forms of hCLCA1 were secreted into the extracellular compartment. Both the 
precursor hCLCA1 and N-terminal product were secreted while the C-terminal product was 
retained inside the cell (Figure 2.4). Similar to previous studies, we also observed an E157Q 
mutation in hCLCA1 abolished the proteolytic activity. A recent study reported that the 
proteolytic activity of hCLCA1 was required to regulate calcium-activated chloride channel 
activity. This study demonstrated that hydrolase-inactive hCLCA1 prevented activation of 
calcium-activated chloride channel-mediated chloride transport70. The author proposed that the 
C-terminal region masks the N-terminal region in the full-length protein, and proteolytic cleavage 
of the full-length protein is required to expose the N-terminal region to interact with the calcium-
activated chloride channel. However, our data demonstrated that hydrolase domain activity was 
not necessary for hCLCA1 to activate airway macrophages45. 
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Figure 2.4. Biosynthesis, glycosylation, and secretion pattern of hCLCA1. Western blot 
analysis of hCLCA1-transfected HEK293 cell lysates and media using (A) N-terminal hCLCA1 
antibody and (B) C-terminal antibody. All precursor, N-terminal, and C-terminal hCLCA1 
products were subjected to glycosylation. Both precursor and N-terminal hCLCA1 were secreted 
into the extracellular compartment. In addition, higher proportion of N-terminal hCLCA1 product 
compared to the precursor was observed. Figure A was modified from the publication: Ching, J. 
C., Lobanova, L. & Loewen, M. E. (2013). Secreted hCLCA1 is a signaling molecule that 
activates airway macrophages. PLoS One 8, e83130. Figure B was from our unpublished data.  
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2.1.2.1.2 Von Willebrand factor type A domain 
 
A von Willebrand factor type A (VWA) domain is predicted between residues 305-458 of 
hCLCA1. Using NCBI’s conserved domain database, hCLCA1’s VWA domain is predicted to 
contain three metal-ion-dependent adhesion site (MIDAS) motifs.  
It is a well-studied domain involved in cell adhesion, in extracellular matrix proteins, and in 
integrin receptors71-73. Studies have also demonstrated that VWA domain was also involved in 
regulating ion channel function. Precedents exist, as the α2δ subunit of the voltage gated calcium 
channel modulates its function by binding to an extracellular region of the channel pore subunit 
via its VWA domain74. Moreover, mutation studies reported that the MIDAS motif in the α2δ 
subunit was essential for its function in channel trafficking and modulation of calcium channel74-
77.  
 
Our unpublished data also demonstrated that the VWA domain of hCLCA1 was responsible for 
macrophage activation (see section 4; Study 2). The MIDAS motifs in hCLCA1 VWA domain 
provide possible active sites that are responsible for macrophage activation. This idea is 
supported by a recent study showing that secreted hCLCA1 increased CaCC conductance37, 
similar to how α2δ subunit of the voltage gated calcium channel modulates its function74.  
 
However, the VWA domain could also execute its function independent of its MIDAS motifs. As 
mentioned above, the β4-binding motif in the VWA domain of hCLCA2 was reported to bind to 
the β4 integrin expressed in breast cancer cells, leading to metastatic spread of the cancer16. A 
similar mechanism was also reported for mCLCA1, in which binding of mCLCA1 and β4 
integrin activated the signaling molecule focal adhesion kinase (FAK), which activated 
downstream extracellular signal regulated kinase (ERK) and promoted proliferation of tumor 
cells49. hCLCA1 has a disrupted β4-binding motif, however this does not exclude the possibility 
that the VWA domain interacts with other proteins with a yet identified domain or binding motif. 
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2.1.2.1.3 Fibronectin type III domain 
 
The fibronectin type III domain lies in the C-terminus of the hCLCA1 protein. It is predicted to 
lie between residues 753-816. Although the function of the FN3 domain in hCLCA1 remains 
unknown, its existence suggests hCLCA1 may act as a signaling molecule. Studies specifically 
on the FN3 domains reported that they interact with β1 integrin and mediate Src-dependent focal 
adhesion kinase (FAK) phosphorylation. This eventually leads to activation of downstream 
signaling to extracellular signal regulated kinase (ERK), in which activated ERK is involved in 
cell migration, proliferation, spreading, and inhibition of apoptosis78, 79. It has also been reported 
that unfolding of the FN3 domain in fibronectin induces expression of cytokines in lung 
fibroblast cells through toll-like receptor (TLR) and nuclear factor-kappa B (NF-κB) pathways80. 
 
2.1.3 Physiological functions of hCLCA1 
 
2.1.3.1  Modulation of calcium-activated chloride channel (TMEM16A) conductance 
 
When hCLCA1 was first identified, it was thought to form the pore subunit of a calcium-
activated chloride channel. Transient expression of hCLCA1 in HEK293 cells increased CaCC 
conductance6. It was later confirmed that the increase in CaCC current by hCLCA1 expression 
was due to regulation of hCLCA1 on endogenous calcium-activated chloride channel 
(TMEM16A)36. TMEM16A was recently identified definitively as the first genuine CaCC in 
mammals81-83. It was concluded that hCLCA1 elevated the conductance of endogenous CaCC by 
lowering the energy barriers for ion translocation. A recent study reported that exogenous 
hCLCA1 increased CaCC current by stabilizing surface expression of TMEM16A37. This agrees 
with our proposed novel function of hCLCA1, in which secreted hCLCA1 can act as a signaling 
molecule to regulate different physiological responses45. 
 
2.1.3.2  Association with mucus expression 
 
Most of the attention on hCLCA1 has been focused on its association with mucus production. 
Epithelial goblet cell hyperplasia and mucus hypersecretion are the hallmarks of patients 
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suffering from inflammatory airway diseases such as cystic fibrosis, chronic obstructive 
pulmonary disease, or asthma43, 84. The excessive mucus production by airway epithelium during 
airway inflammation disrupts normal airway physiology, and this predisposes the host to bacterial 
infection. 
 
The involvement of hCLCA1 or its murine ortholog mCLCA3 with mucus production was first 
identified in 200143. Nakanishi et al. identified mCLCA3 gene to be selectively induced in the 
lungs of an asthmatic mice model. Administration of adenovirus-expressing antisense mCLCA3 
inhibited the development of goblet cell metaplasia and airway hyper-responsiveness while 
overexpression of mCLCA3 exacerbated the asthma phenotype. Nakanishi et al. also 
demonstrated that transient expression of hCLCA1 or mCLCA3 increased mucus production and 
mucin 5AC (MUC5AC) gene expression in NCI-H292 mucoepidermoid cell line43. In the same 
year, Zhou et al. demonstrated that mCLCA3 expression was mediated by T helper (Th)-2 
cytokines (see section 2.3.2.2; Th2 cytokines)85, and Th2 cytokines including Interleukin (IL-)-4, 
IL-9 and IL-13 have been implicated in the regulation of mucus production in airways86-88. 
Beside Th2 cytokines, exposure to tumor necrosis factor-α (TNF-α) also induced mucus 
expression both in vitro and in vivo89-91.  
 
Increased mRNA and protein expressions of hCLCA1 and IL-9, as well as mucus production, 
were detected in the bronchial biopsies samples from asthma, COPD and CF patients44, 92-95. 
Studies demonstrated that stimulation of mucosal tissue from upper airways of CF patients and 
primary normal human bronchial epithelial (NHBE) cells with Th2 cytokines significantly 
increased hCLCA1 and MUC5AC expression39, 96. In addition, intratracheal instillation of IL-13 
in BALB/C mice induced 8- and 110-fold increases in MUC5AC and mCLCA3 mRNA 
expression, respectively. The same study also demonstrated that MUC5AC and mCLCA3 
induction was abolished in Signal Transducer and Activator of Transcription (STAT)-6 knockout 
mice97. However, a lack of STAT6-binding sites in the MUC5AC promoter indicated that 
intermediate steps are required to convert the IL-13 signal to MUC5AC expression98. Soon after, 
the identity of consensus STAT6-binding sites in human and mouse CLCA gene promoter 
regions led to the hypothesis that activation of STAT6 induces CLCAs expression, and in turn 
induces mucin gene expression57. This hypothesis was confirmed by a recent study that IL-13-
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induced hCLCA1 expression activated p38 (see section 2.3.3.2; MAPKs), which sequentially led 
to stimulation of MUC5AC expression (Figure 2.5)41.  
 
Interestingly, although studies have demonstrated that overexpression of mCLCA3 induced 
mucus expression both in vitro and in vivo model systems, a study reported that mCLCA3 
knockout mice showed no difference in mucus production in the presence or absence of pro-
inflammatory cytokines stimuli compared to control mice99. However, this could be attributed to 
the redundancy of CLCA genes in mice, in which other mCLCAs compensate for the loss of 
mCLCA3 function. Precedent exists for this redundancy, the expression of mCLCA5 was found 
to increase in mCLCA3 knockout mice exhibiting goblet cell metaplasia, and mCLCA5 gene 
transfer was shown to be sufficient to drive goblet cell metaplasia in mice54.  
 
Nonetheless, mCLCA3 or hCLCA1 remains to be a potential therapeutic target for goblet cell 
metaplasia. Recently, a study reported that mCLCA3 antibody could dampen the pathological 
symptoms in asthmatic mice55. Asthmatic mice treated with mCLCA3 antibody displayed a 
remarkable reduction in airway inflammation, the number of goblet cells and mCLCA3 
expression in lung tissue55. 
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Figure 2.5. Schematic model of IL-13-induced hCLCA1 regulation of mucin gene 
expression. Interaction of IL-13 and IL-13 receptor leads to STAT6 activation and induction of 
hCLCA1 gene expression. The expressed hCLCA1 then secretes into the extracellular 
compartment and interacts with a putative receptor, and in turn activates p38 that subsequently 
leads to the production of MUC5AC gene expression. This eventually results in mucus 
production in airway mucous cell.  
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2.1.3.3  Regulation of immune response 
 
Recently, we have identified the novel functional role of hCLCA1 as a signaling molecule to 
regulate immune response45. We showed that secreted hCLCA1 could induce pro-inflammatory 
expression in macrophages, and this effect applied to both cell line and primary cells. In our 
unpublished data, we demonstrated that the VWA domain of hCLCA1 was responsible for such 
induction in macrophage via the activation of NF-κB and MAPK pathways. Similar to the study 
that demonstrated hCLCA1 activated p38 to induce mucin gene expression41, we also observed 
correlative activation of p38 in macrophages by the VWA domain of hCLCA1. Shortly after our 
findings that hCLCA1 could activate macrophages, another group reported that mCLCA3 was 
also able to modulate immune response during acute Staphylococcus aureus pneumonia100. This 
study illustrated that mCLCA3 knockout mice had a decrease in neutrophil infiltration into the 
bronchoalveolar space during bacterial infection, and a significant decrease in the mRNA and 
protein expression of IL-17 and IL-8. This study supports our findings that hCLCA1 could 
function as an immune regulator, which might explain the pleiotropic effect of hCLCA1. 
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2.2 Respiratory diseases 
 
The most common chronic airway diseases are cystic fibrosis, asthma, and chronic obstructive 
pulmonary disease101, 102. The hallmarks of these diseases include goblet cell metaplasia, mucus 
hypersecretion, and airway inflammation103-105. High levels of hCLCA1 and pro-inflammatory 
cytokines are found in the airways of patients suffering from these diseases44, 92, 95. hCLCA1 has 
been implicated to play a role in mucus secretion, and pro-inflammatory cytokines (see section 
2.3; Immune response) are responsible for initiating and sustaining inflammation in these airway 
diseases. 
 
2.2.1 Cystic fibrosis 
 
Cystic fibrosis is a life-shortening autosomal recessive disease that affects mainly the exocrine 
pancreas and airways, although it also affects other organs106. It is estimated to affect 1 in 2500-
6000 births depending on the region and ethnic origin, with Caucasians having the highest rate102, 
107, 108. Patients suffering from CF often present with abnormally viscous secretions in the airways 
of the lungs, leading to inflammation, tissue damage and organ destruction103.  
 
This disease is caused by mutations in the gene encoding the cystic fibrosis transmembrane 
conductance regulator (CFTR). CFTR is a cAMP-dependent anion channel expressed in the 
apical membrane of the airway epithelial cells109, 110. Normally, CFTR transports Cl- from 
epithelial cells into the airway. This draws Na+ to follow passively through a paracellular 
pathway to maintain electroneutrality. This causes water to move into the airways by osmosis, 
thus establishing airway surface liquid (ASL) homeostasis to hydrate the airways111, 112. 
Moreover, CFTR is also a known down-regulator of the epithelial sodium channel (ENaC), an 
amiloride-sensitive sodium channel that absorbs Na+ into the cells, which functionally decrease 
the ASL113. This combined effect on Cl- and Na+ transport normally generates an osmotic force 
for water to move across the epithelium into the airways, establishing the ASL and allowing 
appropriate mucociliary clearance112, 114. Mucociliary clearance is a process in which mucus is 
removed from the respiratory epithelium by the beating of cilia.   
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However, the function of CFTR is altered due to mutations in the protein in CF. Absence or 
reduced function of epithelial CFTR leads to alteration of salt and water transport in the airways. 
Malfunction of CFTR causes decreased Cl- secretion and increased Na+ absorption, resulting in 
ASL volume depletion (Figure 2.6)115, 116. This depletion results in abnormal viscous secretions 
that can cause obstruction of airways in the lung, resulting in chronic respiratory infections, 
inflammation, bronchiectasis, and eventually respiratory failure117, 118.  
 
To date, over 1900 CFTR gene mutations associated with CF have been reported to the Cystic 
Fibrosis Mutation Database119. Mutations of CFTR can be grouped into 6 categories according to 
the mechanistic basis: absence of full length CFTR mRNA transcripts (Class I), abnormal folding 
and degradation in ER (Class II), disrupted regulation of channel gating (Class III), abnormality 
of chloride conductance (Class IV), decreased quantities of mature CFTR transcripts (Class V) 
and defect in stability of protein (Class VI)120-124. Out of all the mutations, the class II mutation 
with the deletion of a phenylalanine residue at the 508 position to be the most common in CF, 
accounting for ~70% of all CF chromosomes123.  
 
Although there is currently no cure for CF, there have been major advances in the management of 
CF that resulted in longer survival in the last few decades. The life expectancy of CF patients 
increases from 14 years in 1980’s to 50 years at present in Canada119. Most commonly, CF 
patients use antibiotics to prophylactically suppress lung infection125-127. At present, researches in 
gene therapy and molecule therapy are being conducted in an attempt to cure CF. Gene therapy 
aimed at correcting the genetic alteration by inserting recombinant viral vectors to express 
functional CFTR, but the expression of the introduced gene was short-lasting128. On the other 
hand, there have been promising results in molecular therapy aimed at correcting the functional 
defect in the protein level. Clinical trials on a drug called ivacaftor has demonstrated improved 
lung function in CF patients carrying the G551D (Class III mutation) variant by increasing 
channel activity of both wild type and defective cell-surface CFTR potein120, 129. However, there 
is still a long way to go for CF treatment since there are over 1900 variants associated with CF, 
and the most common CF variants by far is not rescued by drugs such as ivacaftor.   
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Figure 2.6. Overview of major ion channels involved in cystic fibrosis. This diagram 
represents the movement of Na+, Cl- and H2O in normal and CF epithelial cells, as well as their 
respective transporters. The apical side corresponds to the airspace, where the ASL is secreted. 
Normally, CFTR transports Cl- to the airways and down-regulates ENaC function, resulting in 
increased concentration of Na+ in the ASL. This creates strong osmotic drive that draws water to 
the airways, facilitating airway hydration and mucociliary clearance. However, CFTR function is 
impaired in CF, resulting in increased absorption of Na+ into the cells. This leads to airway 
dehydration (decreased in ASL) and mucus build up, contributing to the obstruction of airways in 
the lungs.  
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2.2.1.1  Association of hCLCA1 with CF 
 
The first evidence showing an association of hCLCA1 with cystic fibrosis came from a study 
investigating the protein expression levels from upper airway tissues from CF patients95. The 
study reported that the expression of IL-9, IL-9R and hCLCA1 were increased in biopsy samples 
of nasal polyps, the nasal mucosa and sinus mucosa of CF patients. There was also an increase in 
periodic acid-Schiff stain (PAS)-staining, which indicates increased mucus producing cells in CF 
patients. Positive correlations were found between IL-9, IL-9R and hCLCA1 positive cells, as 
well as between mucus producing and hCLCA1 positive cells95. The same group subsequently 
demonstrated similar results from biopsies of bronchial mucosa of CF patients, further supporting 
the correlations between IL-9, hCLCA1 and mucus overproduction94. To explain the mechanism, 
the same group showed that stimulation with IL-4, IL-9 and IL-13 increased both mRNA and 
protein expression of hCLCA1 in mucosal tissue from upper airways of CF patients96. However, 
mucin protein and MUC5AC mRNA expression were not significantly changed in response to 
Th2 cytokine stimulation. One possible explanation for this observation is that mucosal tissue 
from CF patients already exhibited goblet cell metaplasia; therefore subsequent stimulation with 
Th2 cytokines had minimal effect on mucus expression in the tissues that were already expressing 
high levels of mucus. Lastly, one group performed an association study and reported that 
hCLCA1 was an important modulator for the DIDS-sensitive Cl- secretion in the gastrointestinal 
tract of CF patients46. It suggested that hCLCA1 modulates an alternative chloride secretion 
pathway in CF patients. It is possible that hCLCA1 increases the Cl- secretion through 
TMEM16A to compensate for the loss of CFTR function in the gastrointestinal tract, and the 
same mechanism might occur in the airways as well.   
 
2.2.2 Asthma 
 
Asthma is a chronic inflammatory airway disease characterized by reversible airflow obstruction, 
bronchial hyper-responsiveness, and airway inflammation105. The prevalence of asthma is 
estimated to be 5-10% in the general population, affecting more than 300 million people globally, 
with approximately 250,000 deaths annually101, 130. The symptoms of asthma includes cough, 
shortness of breath, wheezing, chest tightness and excess airway mucus production. 
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The exact cause of asthma is not known, but it is believed that genetic susceptibilities and 
environmental exposures are major factors. Multiple genetic polymorphisms have been 
associated with asthma development131, 132, and parental history of asthma also increases asthma 
susceptibility133. Environmental factors that are associated with asthma pathogenesis include 
aeroallergen sensitization, respiratory viruses, early life microbial exposures, cigarette smoke, air 
pollution, diet and the host microbiome, vitamin D deficiency, antioxidants, and stress134-142.  
 
The hygiene hypothesis has been used to explain the increased rates of asthma since 
industrialization and urbanization (Figure 2.7)143. The hygiene hypothesis proposed that increased 
cleanliness and reduced family size reduced the exposure to bacteria and viruses in early 
childhood144. The biological basis behind this hypothesis is that Th1 cells immune response is not 
induced early in life due to improved sanitary environment145. Many bacteria and viruses elicit 
Th1-mediated immune response, which down-regulates Th2-mediated immune response (see 
section 2.3.1.2; Adaptive immune response)146. However, insufficient induction of Th1-mediated 
immune response renders the body to be more susceptible to induction of Th2-mediated immune 
response. This stimulates the antibody-mediated immunity of the immune system, which in turn 
leads to allergic disease such as asthma136, 147. 
 
Normally, acute inflammation is initiated within minutes of recognition of a danger signal, and it 
resolves itself within hours or days. However, in asthmatic patients, this naturally protective 
response becomes uncontrolled and leads to chronic changes to airway structure and function148. 
Airway inflammation inflicts damages to the airway epithelium, and this leads to airway 
remodeling (Figure 2.8). Airway remodeling is characterized by airway wall thickening, 
subepithelial fibrosis, and goblet cell metaplasia149.  
When the epithelium is injured, it releases profibrotic mediators to facilitate wound healing. 
However, the airway remodeling process persists in asthmatic patients because of the ongoing 
host immune responses that generate mediators150. The pathological consequence of this 
persistent ‘repairing phase’ is thickening of airway wall, which leads to airflow obstruction. The 
airflow obstruction is also intensified with the excess mucus production from the goblet cell 
metaplasia151. As mentioned above, asthma is triggered by stimulation of Th2-mediated immune 
response, and one of the Th2 cytokines secreted is IL-13. Studies have demonstrated that IL-13 is 
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required for goblet cell metaplasia, and this leads to elevated MUC5AC mucin gene 
expression152, 153.  
 
Beside airway wall thickening and goblet cell metaplasia, smooth muscle contraction is a 
prominent contributor to airflow obstruction. Excessive airway narrowing can lead to severe 
shortness of breath, respiratory failure and even death. Smooth muscle contraction can be 
physiologically induced by acetylcholine released from parasympathetic system or by histamine 
and leukotrienes released from mast cells or basophils. In healthy individuals, smooth muscle 
contraction only causes mild airway narrowing in response to these agonists. However, asthma 
patients suffer from bronchial hyper-responsiveness, which results in a substantial increase in 
sensitivity to these agonists. This is demonstrated by a dramatic increase in airway resistance154. 
Interestingly, a study has reported that there was an increase in the expression of calcium-
activated chloride channel TMEM16A in airway epithelial cells of asthmatic patients. The same 
study demonstrated that increased TMEM16A expression contributed to mucus secretion and 
airway smooth muscle hyper-responsiveness155. As mentioned above, hCLCA1 increases CaCC 
current by stabilizing surface expression of TMEM16A. This reinforces the role of hCLCA1 in 
contributing to the pathologies of asthma.  
 
Although there is currently no cure for asthma, symptoms can usually be controlled. Common 
medications include the use of bronchodilators, inhaled corticosteroids, oral leukotriene 
antagonist, or mast cell stabilizer. However, 5-10% of individuals with asthma respond poorly to 
asthmatic drugs, and these severe asthmatic patients are at a relatively high risk for fatal asthma 
attacks156. Numerous clinical trials have been conducted in the recent years, including continuous 
inhaled corticosteroid treatment, continuous or intermittent fluticasone treatment, prednisolone 
treatment, or a combination of long acting beta agonists (LABAs) with fluticasone treatment157-
161. However, these treatments were short-lasting and the effects diminished once administrations 
of drugs were discontinued. In addition, LABAs also induce adverse effects in a small number of 
patients162. Continued research is required to generate new ideas and insights for asthma 
prevention and treatment.  
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Figure 2.7. Overview of association between hygiene hypothesis and asthma. Increased rates 
of asthma have been reported since industrialization and urbanization in the past few decades. 
Although both genetic and environmental factors influence the pathogenesis of asthma, hygiene 
hypothesis is often used to explain the rise of prevalence of allergies or asthma. In urbanized area, 
insufficient stimulation in Th1-mediated immune response early in life predisposes the body to be 
more susceptible to stimulate Th2-mediated immune response, resulting in allergies or asthma. 
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Figure 2.8. Schematic model of increasing severity in airway remodeling. In asthmatic 
patients, persisted airway inflammation leads to airway remodeling. The hallmarks of airway 
remodeling include airway wall thickening, subepithelial fibrosis, myofibroblast hyperplasia, 
goblet cell metaplasia, etc., resulting in severe airway obstruction. The pathophysiological 
consequences of severe airway obstruction can lead to severe shortness of breath, respiratory 
failure, and even death. 
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2.2.2.1  Association of hCLCA1 with asthma 
 
The association of hCLCA1 or its murine ortholog mCLCA3 with asthma first came to light in 
2001. The study identified mCLCA3 to be one of the most highly induced genes in the lungs of 
an asthma mouse model43. Intratracheal administration of adenovirus-expressing antisense 
mCLCA3 RNA effectively suppressed the asthma phenotype including goblet cell metaplasia and 
airway hyper-responsiveness. In addition, the asthma phenotype was worsened when mice were 
administrated an adenovirus-mediated overexpression of mCLCA3. In vitro experiments also 
showed that transient expression of hCLCA1 or mCLCA3 increased mucus production and 
MUC5AC expression in NCI-H292 mucoepidermoid cell line43.  
 
A hallmark of asthma is the overexpression of Th2 cytokines in the airways, which Th2 are 
sufficient to drive mucus over-production86-88. These cytokines also induce hCLCA1 or mCLCA3 
expression both in vitro and in vivo39, 85. Those results demonstrated that hCLCA1 expression is 
mediated by Th2 cytokines, and suggested hCLCA1 as a potential regulator of mucus production. 
To further support this idea, bronchial biopsies samples from asthmatic patients exhibited 
increased the expression of IL-9, IL-9R and hCLCA1, and positive correlations were found 
between these genes and mucus producing cells44. Moreover, a recent study reported that 
administration of mCLCA3 antibody to asthmatic mice significantly reduced the development of 
asthma-associated clinical signs55. In addition, single nucleotide polymorphisms (SNP) in 
hCLCA1 have also been shown to affect patients’ susceptibility to asthma163.  
 
2.2.3 Chronic obstructive pulmonary disease  
 
Chronic obstructive pulmonary disease is defined as “a disease characterized by airflow 
limitation that is not fully reversible. The limitation is usually progressive and associated with an 
abnormal inflammatory response of the lungs to noxious particles or gases” by the Global 
Initiative for Chronic Obstructive Lung Disease (GOLD). The World Health Organization 
(WHO) estimates 65 million people have moderate to severe COPD, and it is one of the leading 
causes of morbidity and mortality worldwide. The typical clinical manifestations of COPD are 
chronic bronchitis and emphysema164. Chronic bronchitis is a condition of chronic inflammation 
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and remodeling in bronchi that results in chronic cough and sputum production. Emphysema is a 
condition of lung parenchyma destruction and alveolar enlargement that results in loss of elastic 
recoil followed by decline in lung function and forced expiration volume. It is clinically accepted 
that chronic inflammation is linked to the lung tissue destruction and alveolar enlargement in 
COPD patients165. 
 
Currently, only one gene is identified to be a risk factor for COPD. Patients with alpha 1-
antitrypsin (ATT) deficiencies are at higher risk for developing COPD104, 166. However, the 
primary risk factor for COPD development is cigarette smoking167. Upon exposure to cigarette 
smoke, respiratory epithelial cells undergo structural alterations that lead to squamous cell 
metaplasia, decreased mucociliary clearance, and loss of barrier function168, 169. Exposure to 
cigarette smoke also induces airway epithelial cells to release inflammatory mediators that result 
in chronic bronchitis170. Goblet cell metaplasia is one of the manifestations of chronic bronchitis, 
and excess mucus remains in the airway due to the reduced mucociliary clearance, leading to 
chronic cough, sputum production and infection.  
 
As inflammation in the lung progresses, large numbers of macrophages and neutrophils infiltrate 
the lung parenchyma, leading to emphysema171, 172. The accumulation of these inflammatory cells 
serves as a self-perpetuating stimulus for further immune activation, leading to severe lung 
injury. Macrophages from COPD patients have been shown to secrete increased levels of IL-8, 
which further promotes neutrophil infiltration173. In addition, neutrophil phagocytosis by alveolar 
macrophages has been found to be impaired in COPD, resulting in persistent neutrophil 
infiltration in the lung174. 
 
A protease-antiprotease balance theory has been hypothesized to explain the development of 
emphysema175. This hypothesis proposes that under inflammatory environments such as exposure 
to cigarette smoke, neutrophils and macrophages secrete excess elastases and matrix 
metalloproteinases (MMP) which facilitate the destruction of lung parenchyma (Figure 2.9)176, 
177. It is evident that elastase-deficient mice and MMP knockout mice displayed higher resistance 
to develop emphysema with chronic cigarette smoke exposure178, 179. Recent studies also 
supported the idea that emphysema is partly due to a decrease of endothelial cell maintenance 
	 43	
factors. One example of this is vascular endothelial growth factor (VEGF). It was reported that 
the expressions of VEGF and its receptor were significantly decreased in COPD patients, which 
promoted apoptosis of alveolar wall cells and emphesema180, 181. 
 
There is currently no cure for COPD, however, the clinical symptoms can be improved. Cessation 
of cigarette smoking is considered to be the most important aspect of COPD management. 
Although the decline of lung function persists after cigarette cessation, the rate of decline is 
reduced182. Other non-pharmacological approaches include reducing the risk for infection through 
vaccination against influenza or pneumococcus, pulmonary rehabilitation, and oxygen 
supplementation. Amongst pharmacological approaches, the primary medications are 
bronchodilators, which have been shown to significantly reduce COPD exacerbations183. Other 
pharmacological interventions include the use of antioxidants, anti-inflammatory drugs, and 
antibiotics. Although many non-pharmacological managements and pharmacological approaches 
are available to reduce COPD exacerbations, the degree of reduction is usually limited. 
Therefore, novel approaches are needed to prevent the progression of the disease. 
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Figure 2.9. Impact of cigarette smoking in the development of COPD. Cigarette smoking is a 
primary factor for the development of COPD, and the clinical manifestations are chronic 
bronchitis and emphysema. Cigarette smoke exposure induces inflammation and facilitates 
macrophage and neutrophil infiltration. These inflammatory cells then secrete tissue-destroying 
enzymes to disintegrate alveolar wall, leading to emphysema. The pathophysiological 
consequences of emphysema include significant decrease in lung function and forced expiration 
volume. 
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2.2.3.1  Association of hCLCA1 with COPD 
 
Although most of the studies on hCLCA1 have been focused on its association with asthma, 
several studies have linked hCLCA1 with COPD. Similar to asthma and CF, biopsies of 
bronchial samples from COPD patients displayed markedly increase in IL-9, IL-9R, hCLCA1 
and mucus expression92. Increased expression of eCLCA1, equine ortholog of hCLCA1, was also 
observed in horses with recurrent airway obstruction. Recurrent airway obstruction is a common 
spontaneous disease in horses with high clinical, functional, and pathological similarities to 
human asthma and COPD184, 185. It is well-known that cigarette smoking is a primary risk factor 
for COPD development. A study demonstrated that expression of MUC5AC and rCLCA1, rat 
ortholog of hCLCA1, were up-regulated in rats exposed to cigarette smoke84. In the same study, 
the author also showed that expression of hCLCA1 and MUC5AC were up-regulated in H292 
mucoepidermoid cell line exposed to smoke solution. Moreover, twenty-two SNPs were 
identified in hCLCA1 that were associated with COPD, and the author suggested that SNPs in 
hCLCA1 could be a useful indicator for COPD susceptibility186.  
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2.3 Immune response 
 
2.3.1 Overview of innate and adaptive immune system 
 
The immune system is a collection of cells and proteins that functions to protect an organism 
from foreign antigens such as microbes, viruses, cancer cells, and toxins. The immune system can 
be classified into the innate immune system and the adaptive immune system. An adaptive 
immune response is called into action when the innate immune response has failed to eliminate 
the pathogen. 
 
2.3.1.1  Innate immune response 
 
The innate immune system constitutes the first line of defense against an intruding pathogen. It is 
a non-specific defense mechanism which is initiated within hours after the host encounters an 
antigen. The primary function of innate immunity is to trigger inflammation and recruit immune 
cells to sites of infection. 
 
There are many conserved features of pathogens that are common to many pathogens but are 
absent in the host. These pathogen-associated molecular patterns (PAMPs) allow the host’s 
immune system to distinguish between self and non-self antigens. For example, molecules found 
on the surface of many microorganisms do not occur in mammalian cells. These include the 
peptidoglycan cell wall and flagella of bacteria, as well as lipopolysaccharide (LPS) on Gram-
negative bacteria and lipoteichoic acids on Gram-positive bacteria187. PAMPs are then recognized 
by the pattern recognition receptors (PRRs) expressed on the surface of immune cells such as 
resident macrophages, dendritic cells, neutrophils, and epithelial cells188. The most well-studied 
PPRs in humans are toll-like receptors (TLRs). Interaction of PAMPs with their specific TLRs 
induces the activation of NF-κB signaling and MAPK pathways, which causes secretion of pro-
inflammatory cytokines189. Cytokine production also leads to the release of antibodies and other 
proteins and glycoproteins that activates the complement system. The complement system is part 
of the innate immune system that involves a series of biochemical cascades. There are three ways 
in which the complement system protects against infection. First, it generates activated 
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complement proteins to identify and opsonize foreign antigens, predisposing them to 
phagocytosis by phagocytes including macrophages or neutrophils. Second, the small fragments 
of some complement proteins act as chemoattractants to recruit more phagocytes to the site of 
infection. Third, complement proteins assemble a membrane-attack complex to create a pore in 
the lipid bilayer membrane of the bacteria to destroy membrane integrity190. 
 
After recognizing PAMPs, resident macrophages become activated and drive the influx of 
inflammatory leukocytes such as neutrophils and monocytes through chemokine secretion. 
Neutrophils are the earliest cells recruited to the site of inflammation. They phagocytose and then 
destroy pathogens in the phagosomes by producing reactive oxygen species and through the 
action of hydrolytic enzymes191. After ~48 hours, monocytes are recruited to the site of 
inflammation and differentiate into either macrophages or dendritic cells. The dendritic cells and 
macrophages are antigen-presenting cells (APCs) that phagocytose and process pathogens, and 
present processed antigens on their major histocompatibility complex (MHC) class II molecules 
to initiate an adaptive immune response190. In addition, macrophages are also responsible for 
eliminating aged neutrophils via a process called efferocytosis and initiate immune resolution 
(Figure 2.10)192. However, when foreign particles are still present, activated macrophages 
perpetuate inflammation by recruiting more leukocytes and secreting pro-inflammatory 
cytokines. During airway inflammation, pro-inflammatory cytokines and hCLCA1 were reported 
to be up-regulated in the airways92, 193, and we demonstrated that hCLCA1 could act as a 
signaling molecule to induce pro-inflammatory cytokine expression in macrophages45, thereby 
enhancing inflammation, and increasing immune cells infiltration. A recent study also reported 
that mCLCA3 knockout mice displayed decreased neutrophil infiltration in acute Staphylococcus 
aureus pneumonia100. Together, these studies further support the role of hCLCA1 in regulation of 
the immune system. 
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Figure 2.10. Overview of innate immune response. Macrophages become activated when they 
detected PAMPs through their PRRs. This induces macrophages to increase expression of pro-
inflammatory cytokines and chemokines, leading to an influx of neutrophil infiltration to the site 
of inflammation. Neutrophils phagocytize and destroy pathogens through reactive oxygen species 
and hydrolytic enzyme. After 48 hours, additional macrophages are recruited to the site of 
infection to eliminate aged neutrophils and initiate immune resolution. If the inflammation 
persists, additional immune cells such as macrophages and dendritic cells will be recruited, 
resulting in the initiation of adaptive immune response. In addition, hCLCA1 or mCLCA3 
secreted from inflamed epithelial cells also play a role in the innate immune response. Our work 
showed that hCLCA1 could induce pro-inflammatory cytokines expression in macrophages. 
Another study demonstrated that mCLCA3 was involved in neutrophil recruitment during 
bacterial infection in mice.  
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2.3.1.2  Adaptive immune response 
 
Adaptive immunity is an antigen-dependent and antigen-specific mechanism that is called into 
action against pathogens that are able to evade or overcome innate immune defenses. The 
primary function of adaptive immunity is to eliminate specific pathogens or pathogen-infected 
cells and the development of an immunologic memory that can quickly eliminate the same 
pathogen in the future194. The main players of adaptive immunity include antigen-presenting cells 
(APCs), T cells, and B cells. These cells are all derived from hematopoietic stem cells in the bone 
marrow, and they are subsequently developed into different specific types based on different 
stimulants. 
 
Pathogens are first ingested by antigen-presenting cells (APCs), which are usually dendritic cells, 
but also macrophages, B cells, fibroblasts and epithelial cells. APCs process the pathogens and 
subsequently present the antigens on major histocompatibility complex (MHC) molecules. MHC 
can be classified as either class I which are found on all nucleated cells, or class II which are only 
found on macrophages, dendritic cells and B cells. MHC class I molecules present endogenous 
antigens (cells infected with pathogens) while MHC class II molecules present exogenous 
antigens (phagocytosis of the pathogens). T cells become activated when their T-cell receptor 
(TCR) recognize an antigen-MHC complex on an APC. Binding of MHC class I molecules 
activate cytotoxic T cells while binding of MHC class II molecules activate T helper cells. 
Subsequently, activated T helper cells (Th2) are involved in differentiating B cells into either 
plasma cells or memory B cells. 
 
2.3.1.2.1 Cytotoxic T cells 
 
Activated cytotoxic T cells undergo clonal expansion in which they produce effector cells, and 
the effector cells search for pathogen-infected cells that have presented the antigens on the MHC 
class I molecules on the surface of the cells. Interaction of their TCRs and the MHC class I 
molecules on infected cells lead to the release of perforin, granzyme or granulysin to the infected 
cells, which results in either cell lysis or apoptosis. Upon resolution of the infection, most of the 
effector cells will die and be cleared by phagocytes. However, a subset of them are retained as 
	 50	
memory cells and can quickly differentiate into effector cells upon future encounters with the 
same antigen194. 
 
2.3.1.2.2 T helper cells 
 
Naïve T helper (Th) cells are activated when their TCRs interact with MHC class II molecules. 
Although T helper cells have no cytotoxic or phagocytic activity, they mediate immune responses 
by directing other cells to eliminate pathogens. Once activated, naïve Th cells can differentiate 
into either Th1 or Th2 cells depending on the stimulant195.  
 
Activated Th1 cells are characterized by their capacities to produce interferon-gamma (IFN-γ), 
TNF-α and IL-12, which activate macrophages to kill microbes located within their phagosomes, 
activate cytotoxic T cells to kill infected cells, and induce B cells to make opsonizing and 
neutralizing antibodies. If naïve Th cells are differentiated into Th2 cells, they secrete IL-4, IL-5, 
IL-10 and IL-13 to defend the host against extracellular pathogens. Th2 cells can stimulate B 
cells to make most classes of antibodies, including immunoglobin (Ig)-E and some subclasses of 
IgG antibodies that bind to mast cells, basophils and eosinophils. Binding of IgE antibodies 
stimulates mast cells and basophils to release histamine, which increases the permeability of the 
capillaries to immune cells. Mast cells and eosinophils are responsible for initiating acute 
inflammatory responses such as allergy or asthma, and IgE antibodies are also associated with 
allergic reactions. These cells release local mediators that cause sneezing, coughing, or diarrhea 
and help expel extracellular pathogens from epithelial surfaces of the body. Similar to cytotoxic T 
cells, a few of Th cells remain as Th memory cells upon resolution of infection194. In general, Th1 
responses are more effective against intracellular pathogens, whereas Th2 responses are more 
effective against extracellular pathogens such as parasites.  
 
2.3.1.2.3 B cells 
 
Unlike T cells, B cells can recognize pathogen via the antigen receptors on the surface of the B 
cells, and they ingest the pathogens using receptor-mediated endocytosis. The pathogens are then 
degraded, processed, and displayed on the MHC class II molecules of B cells. This attracts 
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activated Th2 cells to bind to the MHC class II molecules and provide cognate assistance, 
resulting in the B cell proliferation and differentiation into antibody-secreting plasma cells or 
memory B cells. Plasma cells produce pathogen-specific antibodies, which help eliminate the 
pathogens through the complement cascade. Memory B cells are long-lived B cells which can 
readily elicit an antibody-mediated immune response upon subsequent infections with the same 
pathogen (Figure 2.11)194. 
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Figure 2.11. Overview of adaptive immune response. 1) Pathogens are first ingested by APCs 
such as macrophages and dendritic cells, then the pathogens are processed and presented on 
APCs with either MHC class I or MHC class II molecules. T cells become activated when their 
T-cell receptor interacts with the MHC complex on APCs. 2) Binding of MHC class I molecules 
activate cytotoxic T cells while 3) binding of MHC class II molecules activates naïve T helper 
cells. Activated cytotoxic T cells are responsible for destroying infected cells. Activated naïve T 
helper cells differentiate into either Th1 or Th2 cells. Th1 cells secrete cytokines to enhance the 
microbicidal activity of macrophages, enhance killing ability of cytotoxic T cells, and induce B 
cells to produce opsonizing and neutralizing antibodies. Whereas, 4) Th2 cells stimulate B cells 
to produce other subclasses of antibodies to attract different immune cells for the complement 
cascade. 5) When B cells detect pathogens through their antigen binding receptor, they ingest and 
process the pathogens and present them on their MHC class II molecules. This facilitates 
interaction with Th2 cells, which leads to proliferation and differentiation of B cells into either 
plasma cells or memory B cells. Plasma cells are responsible for producing antibodies to initiate 
the complement cascade to eliminate the pathogens, while memory B cells are responsible for 
preparing the host to elicit quick responses upon subsequent infection by the same pathogens.  
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2.3.2 Cytokines in airway diseases 
 
Cytokines are important mediators that play roles in orchestrating the inflammation in airway 
diseases such as asthma and COPD by recruiting, activating, and promoting the survival of 
different inflammatory cells in the respiratory tract (Table 2.3). Generally, cytokines are 
categorized into four groups: Th1, Th2, pro-inflammatory, and anti-inflammatory cytokines. In 
these chronic airway diseases, Th1 and pro-inflammatory cytokines are responsible for initiating 
and sustaining airway inflammation. Th2 cytokines are suggested to contribute to mucus 
hypersecretion, airway hyper-responsiveness, and subepithelial fibrosis. On the other hand, anti-
inflammatory cytokines are important for immune resolution. 
 
Bronchial biopsies from asthmatic patients showed increased filtration of eosinophils, activated 
mast cells, and Th2 cells196. On the other hand, bronchial, small airways and lung parenchyma 
biopsies from COPD patients showed increased filtration of Th1 cells, neutrophils, and 
macrophages197. These inflammatory cells are largely responsible for the inflammatory 
phenotypes observed in asthma and COPD patients by secreting different cytokines. However, as 
the severity of these airway diseases worsens, this specific Th-mediated distinction (asthma is 
Th2 and COPD is Th1) becomes indistinguishable. 
 
2.3.2.1  Th1 cytokines 
 
IFN-γ is the predominant cytokine produced by Th1 cells that are highly expressed in the airways 
of COPD patients, but its expression is reduced in asthmatic patients198, 199. IFN-γ is an important 
mediator for inducing Th1 cytokines expression while suppressing the Th2 cytokines 
expression200. It also facilitates cytotoxic T cells and Th1 cell infiltration in the lungs by up-
regulation of chemokines receptors and chemokines201. In addition, IFN-γ is also responsible for 
priming macrophages for microbicidal functions. 
 
IL-12 is a key player in host defense by promoting the survival and growth of Th1 cells, and it is 
produced by activated macrophages, dendritic cells, and airway epithelial cells202. IL-12 has a 
crucial role in the induction of IFN-γ production by Th1 cells, as well as increasing cytotoxicity 
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of natural killer (NK) cells and cytotoxic T cells203, 204. Similar to IFN-γ, the expression of IL-12 
is higher in COPD but not in asthmatic patients198, 205.  
 
IL-18 is a pro-inflammatory cytokines that is produced in macrophages. It was initially 
discovered as an IFN-γ-inducing factor, it was later found that IL-18 also stimulates the 
production of other pro-inflammatory cytokines, chemokines, and transcription factors206. IL-18 
synergizes with IL-12 to activate T cells and NK cells for IFN-γ production, inhibition of IL-4-
dependent IgE production, and the suppression of Th2 response. In individuals with COPD, IL-
18 expression was increased in alveolar macrophages and cytotoxic T cells in the airways and is 
correlated with disease severity207. 
 
2.3.2.2  Th2 cytokines 
 
IL-4 induces naïve Th cells to differentiate into Th2 cells. Upon activation by IL-4, Th2 cells 
subsequently produce additional IL-4 to facilitate Th2 cell proliferation in a positive feedback 
manner. It is an important mediator for isotype switching of B cells from producers of IgG to 
producers of IgE, which is associated with hypersensitivity and allergic reactions193. IL-4 also 
suppresses the differentiation of Th1 cells by antagonizing the production of IFN-γ and IL-12 in 
macrophages and Th1 cells. In addition, IL-4 is responsible for promoting wound-healing 
macrophages, resulting in fibrogenesis and tissue repair (see section 2.4.2.2.1; wound-healing 
macrophage)208. IL-4 has also been shown to induce mucus production, and together with 
fibrogenesis of wound-healing macrophages, contributing to the airway remodeling of asthma 
patients86. 
 
Similar to IL-4, IL-9 is highly induced in individuals suffering from airway diseases such as CF, 
asthma, and severe COPD44, 92-95. A study reported that overexpression of IL-9 in mice induced 
eosinophil infiltration, mucus hyperplasia, mastocytosis, airway hyper-responsiveness, and 
increased expression of other Th2 cytokines and IgE209. Another study showed that many of these 
effects were mediated by IL-13, and overexpression of IL-9 in IL-13 knockout mice did not 
induce mucus production and pulmonary eosinophil infiltration210.  
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IL-13 has been attracting a lot of attentions as a therapeutic target for asthma treatment because it 
has been shown to induce airway hyper-responsiveness, mucus metastasis, airway smooth muscle 
proliferation, and subepithelial fibrosis211. Similar to IL-4, IL-13 also promotes macrophages to 
differentiate into wound-healing macrophages. In addition, like other Th2 cytokines, IL-13 
expression was increased in airways of asthmatic patients, whereas it was reduced in patients 
with severe COPD212. As mentioned above (see section 2.1.3.2; hCLCA1’s association with 
mucus expression), studies reported that IL-13 induced the expression of hCLCA1 through 
STAT6 pathway, and hCLCA1 subsequently induced MUC5AC gene expression through 
activation of p3841, demonstrate the role of hCLCA1 in the pathology of asthma.   
 
2.3.2.3  Pro-inflammatory cytokines 
 
Pro-inflammatory cytokines such as TNF-α, IL-6, and IL-1β were increased in the sputum and 
bronchoalveolar lavage (BAL) fluid in asthmatic and COPD patients193. Although monocytes and 
macrophages are the main sources of these cytokines, they are also produced by activated 
lymphocytes, endothelial cells, and fibroblasts213. Expression of these pro-inflammatory 
cytokines is in part mediated through activation of the NF-κB and MAPK pathways.  
 
TNF-α is one of the first pro-inflammatory cytokines to be released in response to pathogens. It 
induces vasodilation and increased vascular permeability, facilitating infiltration of lymphocytes, 
neutrophils, and monocytes. It also helps recruitment of these immune cells to the site of 
inflammation by regulating chemokine release213. TNF-α is suggested to play a critical role in 
amplifying inflammation via activation of the NF-κB pathway in asthmatic patients in a positive 
feedback manner214. In addition, TNF-α promotes classical activation of macrophages (see 
section 2.4.2.1; classical activation of macrophage), which perpetuate inflammation by releasing 
increased levels of pro-inflammatory cytokines including IL-1β, IL-6, and additional TNF-α215. 
 
IL-1β is mainly produced in monocytes and macrophages. It is a potent pro-inflammatory 
cytokine that induces the release of chemokines and vascular adhesion molecules, promoting 
monocyte infiltration in early inflammation216, 217. IL-1β also induces expression of itself in 
newly recruited monocytes, thus reinforcing the overall process218. IL-1β expression was reported 
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to increase in the airways of asthmatic patients, and it initiated the production of other pro-
inflammatory cytokines. In individuals with COPD, IL-1β was reported to activate macrophages 
to secrete inflammatory cytokines, chemokines, and MMP173. As mentioned in previous section, 
MMP is responsible for destruction of lung parenchyma by degrading extracellular matrix 
(ECM)176. 
 
IL-6 is a pleiotropic cytokine that has both pro-inflammatory and anti-inflammatory functions. It 
provides a link between innate and adaptive immunity by promoting differentiation of B cells 
into plasma cells and activating cytotoxic T cells213. Similar to TNF-α and IL-1β, IL-6 is 
responsible for recruiting monocytes to the site of inflammation219. However, IL-6 also plays a 
role in anti-inflammation by inhibiting the production of TNF-α and IL-1β220. Consistent with 
other pro-inflammatory cytokines, increased expression of IL-6 was found in the sputum of both 
asthmatic and COPD patients221, 222. IL-6 might play a role in controlling the degree of 
inflammation in chronic airway diseases. 
 
IL-8, also known as neutrophil chemotactic factor, is a potent chemoattractant for neutrophils that 
is produced mainly in activated macrophages. IL-8 levels were markedly increased in the sputum 
of COPD and asthma patients, and its expression is correlated with the numbers of neutrophils in 
the sputum223, 224.   
 
2.3.2.4  Anti-inflammatory cytokines 
 
IL-10 is a potent anti-inflammatory cytokine that is mostly produced by monocytes and 
regulatory macrophages. IL-10 inhibits the production of many pro-inflammatory cytokines that 
are overexpressed in asthma and COPD, by interfering with the activation of NF-κB and MAPK 
pathways225-227. IL-10 suppresses the expression of MHC class II molecules in activated 
macrophages, indirectly suppressing the activation of T helper cells226. In addition, macrophages 
exposed to IL-10 exhibited reduced microbicidal activity and their capacities to respond to IFN-
γ228, 229. However, expressions of IL-10 were decreased in individuals with asthma and COPD230, 
231. 
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Table 2.3. Key cytokines involved in asthma and COPD. 
 
Cytokines Expression 
in asthma 
Expression 
in COPD 
Main functions 
Th1 cytokines 
IFN-γ Decreases Increases Induces expression of Th1 cells 
Suppresses expression of Th2 cells 
Primes macrophages for microbicidal activity 
IL-12 Decreases Increases Induces IFN-γ production in Th1 cells 
IL-18 Decreases Increases Induces IFN-γ production in Th1 cells 
Inhibits IL-4-dependent IgE production 
Th2 cytokines 
IL-4 Increases Decreases Facilitates Th2 cells proliferation 
Promotes isotype switching of B cells 
Antagonizes IFN-γ and IL-12 production 
IL-9 Increases Decreases Induces eosinophil infiltration 
Induces mucus hypersecretion 
Increases expression of other Th2 cytokines 
IL-13 Increases Decreases Induces airway hyper-responsiveness 
Increases hCLCA1 expression 
Promotes wound-healing macrophages 
Pro-inflammatory cytokines 
TNF-α Increases Increases Facilitates immune cells infiltrations 
Promotes classical activated macrophages 
Amplifies inflammation 
IL-1β Increases Increases Promotes monocyte infiltration 
Induces macrophages to induce inflammatory 
response 
IL-6 Increases Increases Promotes differentiation of plasma cells 
Activates cytotoxic T cells 
Facilitates monocyte infiltration 
IL-8 Increases Increases Recruits neutrophils to the site of 
inflammation 
Anti-inflammatory cytokines 
IL-10 Decreases Decreases Inhibits the production of pro-inflammatory 
cytokines 
Interferes NF-κB and MAPK pathways 
Suppresses the expression of MHC class II 
molecules in macrophages 
Suppresses the activity of T helper cells 
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2.3.3 Signal transduction pathways in airway diseases 
 
2.3.3.1  Nuclear factor-kappa B  
 
Nuclear factor-kappa B is viewed as a master regulator of the inflammatory response because it 
plays a pivotal role in regulating the immune response (Figure 2.12). It is involved in a major 
regulatory signal transduction pathway that regulates genes responsible for both the innate and 
adaptive immune response. NF-κB usually exists as a heterodimeric complex of p50 and p65 
subunits232. NF-κB is normally sequestered in the cytoplasm with an inhibitory protein called 
inhibitory κB (IκB)-α, which masks the nuclear translocation signal and prevents NF-κB from 
translocating into the nucleus. Following exposure to NF-κB inducers such as TNF-α, IL-1β, LPS 
and oxidative stress, IκB-α become phosphorylated and subsequently results in ubiquitination and 
degradation233. This allows the translocation of free NF-κB into the nucleus, where it binds to the 
promoter of target genes and regulates their transcription. Activation of NF-κB leads to up-
regulation of many genes including chemokines, immune receptors, vascular adhesion molecules, 
stress response genes, regulators of apoptosis, transcription factors, growth factors, and pro-
inflammatory cytokines such as IL-8, IL-1β, TNF-α, IL-6234-237.  
 
Activated NF-κB has been reported in individuals suffering from asthma, COPD, and CF, and it 
was implicated to contribute to the pathogenesis of these airway diseases238-240. Studies 
demonstrated that p50 knockdown mice display reduced pulmonary inflammation and airway 
hyper-responsiveness after ovalbumin challenge, and this was because p50 knockdown mice were 
deficient in producing chemokines that are responsible for recruiting eosinophils and T cells to 
the sites of inflammation241, 242. It was later confirmed by other groups that activation of NF-κB 
within airway epithelium was essential to induce airway inflammation in asthmatic mice243, 244. In 
the case of COPD, oxidative stress generated by cigarette smoking was reported to induce 
inflammation through activation of NF-κB and by inducing the release of pro-inflammatory 
mediators such as IL-8 and IL-1β245. Furthermore, a study reported that IL-8 was significantly 
induced in the BAL fluid of CF patients, and this IL-8 induction was attributed to the activation 
of NF-κB246. These results agree with our novel identified function of hCLCA1 as an 
inflammatory mediator. hCLCA1 is one of the most induced genes in airway diseases, and our 
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works have demonstrated that it could activate NF-κB pathway to induce pro-inflammatory 
cytokines. This is further supported by another study that concluded mCLCA3, murine ortholog 
of hCLCA1, mediated neutrophil infiltration via up-regulation of IL-8100, and it is likely to be 
NF-κB-dependent as well. 
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Figure 2.12. Brief overview of NF-κB pathway. NF-κB (heterodimer of p50 and p65 
molecules) is normally sequestered in the cytoplasm by IκB-α. Upon exposure to stimuli such as 
TNF-α, IL-1β, LPS, and oxidative stress, IκB-α becomes phosphorylated and subsequently 
becomes ubiquitinated and degraded. This allows free NF-κB to translocate into the nucleus and 
bind to the promoters of target genes. Activation of NF-κB induces transcription of pro-
inflammatory cytokines, chemokines, immune receptors, vascular adhesion molecules, stress 
response genes, regulators of apoptosis, transcription factors, and growth factors.   
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2.3.3.2  Mitogen-activated protein kinases  
 
Mitogen-activated protein kinases (MAPKs) are important components of signaling modules that 
are involved in acute inflammatory responses in airway diseases. MAPKs are classified into three 
groups: the extracellular signal regulated kinase (ERKs), p38, and the c-Jun N-terminal 
kinase/stress-activated protein kinases (JNK/SAPKs) (Figure 2.13). Upon exposure to stimuli, 
MAPKs are converted into activated forms via phosphorylation cascade, allowing their 
interactions with cytoplasmic substrates and translocations to the nucleus, where many MAPK 
targets, such as transcription factors and histones, are located247. The ERK pathway is stimulated 
by G-protein coupled receptors and growth factors, resulting in gene expression involved in 
proliferation, differentiation, and survival. The p38 and JNK pathways are activated mainly by 
cytokines, leading to gene expression involved in inflammation and apoptosis248. Studies have 
reported that patients with airway diseases such as CF, asthma, and COPD demonstrated 
increased phosphorylated forms of MAPKs, therefore, MAPKs are suggested to play an 
important role in mediating airway and lung inflammation249-251.  
 
Activation of ERK typically induces the expression of genes involved in proliferation, 
differentiation, and growth. However, studies have demonstrated that ERK also played a role in 
mediating inflammation by regulating the expression of different pro-inflammatory cytokines 
such as IL-6, IL-8, and IL-1β252. A recent study demonstrated that an ERK inhibitor was 
sufficient to suppress the expression of pro-inflammatory cytokines in H292 mucoepidermoid 
cells exposed to cigarette smoke condensate253. Beside ERK, p38 is also activated in COPD 
patients. Activation of p38 was reported to stabilize the mRNA of many pro-inflammatory 
cytokines and chemokines involved in COPD pathogenesis, and inhibition of p38 was reported to 
sufficiently attenuate the disease severity in animal models of COPD254, 255. This agrees with a 
subsequent study demonstrating inhibition of p38 pathway reduced the expression of TNF-α, IL-
6, and IL-1β256. Similar to COPD, inhibition of ERK and p38 reduced the stability of IL-8 mRNA 
in cystic fibrosis lung epithelial cell line, while inhibition of JNK had no effect251. In the case of 
asthma, there was a positive correlation between disease severity and the amount of 
phosphorylated ERK and phosphorylated p38, as well as between phosphorylated ERK and the 
number of infiltrated eosinophils and neutrophils in the airways249. It is important to note that 
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activation of ERK and p38 have been shown to subsequently activate NF-κB pathway. In our 
work, we have demonstrated that hCLCA1 induced expression of pro-inflammatory cytokines via 
activation of ERK, p38, and NF-κB pathway. It is possible that hCLCA1 initially activates ERK 
and p38, which subsequently activates NF-κB to regulate inflammation. 
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Figure 2.13. Brief overview of MAPK pathways. Upon exposure to stimuli, MAPKs (ERK, 
p38, and JNK) are activated via phosphorylation cascade. Activated MAPKs translocate into the 
nucleus and activate MAPK targets including transcription factors and histones. Activation of 
ERK pathway leads to gene expression involved proliferation, differentiation, and survival. 
Activation of p38 pathway induces gene expression involved in cytokine production, 
inflammation, and apoptosis. Last but not the least, activation of JNK pathway leads to gene 
expression responsible for inflammatory response and apoptosis.  
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2.4 Macrophage – biology and function 
 
2.4.1 Origin and Recruitment 
 
Macrophages are a type of immune cells that are located throughout the body. They phagocytose 
foreign particles, dead cells and debris and recruit additional neutrophils and macrophages in 
response to inflammatory signals. They are also one of the most important antigen-presenting 
cells (APCs) regulating the immune response in the body. They are differentiated from 
circulating monocytes, which migrate into tissue in both inflammatory and non-inflammatory 
states257. Monocytes are derived from hematopoietic stem cells in the bone marrow, which are 
also precursors of neutrophils, eosinophils, basophils, macrophages, dendritic cells and mast 
cells. Haematopoietic stem cells sequentially develop into monocytes, in which they are released 
from the bone marrow into the bloodstream.  
 
During inflammation, monocytes are recruited to the site of inflammation via chemotaxis. 
Chemokines can be generated from damaged cells, pathogens, or resident macrophages at the site 
of inflammation. Circulating monocytes then extravasate through the endothelium of a blood 
vessel and enter the site of inflammation. Monocytes quickly differentiate into macrophages, and 
it was shown that the majority of the recruited macrophages displayed inflammatory 
characteristics258. 
 
2.4.2 Mode of activation 
 
Macrophages can be activated into two different groups depending on stimuli: classically 
activated macrophages and alternatively activated macrophages. Alternatively activated 
macrophages can further be classified into two sub-populations: wound-healing macrophages and 
regulatory macrophages (Figure 2.14). Macrophages are highly plastic; i.e., how they are 
activated determines their functions. This characteristic allows macrophages to reversibly switch 
between different phenotypes depending on the microenvironment.  
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2.4.2.1  Classical activation 
 
Classically activated macrophages play a role as effector cells in Th1-mediated immune response. 
These macrophages have enhanced microbicidal capacity and are able to secrete high levels of 
pro-inflammatory cytokines and mediators259. A combination of two signals is required to 
classically activate macrophages, and they are IFN-γ and TNF. IFN-γ is secreted from other 
immune cells during stress or infection, and this cytokine primes macrophages to secrete pro-
inflammatory cytokines. This promotes macrophages to produce increased amounts of superoxide 
anions and oxygen and nitrogen radicals to increase their microbicidal ability260. However, TNF 
or inducer of TNF is required as a second signal in order for full activation. Although exogenous 
TNF can act as the second signal, but toll-like receptor ligand such as LPS is a more 
physiologically relevant agonist. Macrophages induce the expression of TNF when exposed to 
LPS, and the expressed TNF can cooperate with IFN-γ to activate macrophages in an autocrine 
manner215.  
 
When macrophages are classically activated, they secrete high levels of pro-inflammatory 
cytokines such as TNF, IL-12, IL-1 and IL-6. They also secrete increased levels of chemokines 
such as interferon gamma-induced protein 10 (IP-10), macrophage inflammatory protein 1α 
(MIP-1α), and monocyte chemotactic protein 1 (MCP-1) to recruit additional macrophages to the 
site of inflammation to sustain the inflammation215. Although classical activated macrophages are 
vital components of host defense, the cytokines and mediators they produced can also lead to 
host-tissue damage.  
 
2.4.2.2  Alternative activation 
 
2.4.2.2.1 Wound-healing macrophages 
 
As the name suggests, wound-healing macrophages are responsible for wound-healing, 
angiogenesis, and ECM deposition. The major signals that promote wound-healing macrophages 
are IL-4 and IL-13208. Basophils and mast cells are important early sources of IL-4 following 
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tissue injury261. The wound-healing macrophage population is sustained by a Th2-mediated 
immune response, in which the signature cytokines are IL-4 and IL-13.  
 
Contrary to classically activated macrophages, wound-healing macrophages fail to present 
antigen, produce little pro-inflammatory cytokines, and are inefficient at killing intracellular 
pathogens262. However, these cells secrete components of the extracellular matrix and contribute 
to tissue repair. Wound-healing macrophages produce high levels of fibronectin and transforming 
growth factor-β1 (TGFβ1), which promote fibrogenesis from fibroblastoid cells263. They also 
display enhanced arginase activity that leads to polyamine and proline biosynthesis, promoting 
cell growth, collagen formation and tissue repair264. Similar to classically activated macrophages, 
dysregulation of their matrix-repairing ability in wound-healing macrophages can lead to tissue 
fibrosis. Accumulating evidence suggests that these macrophages may contribute to the airway 
remodeling of asthmatic patients265. 
 
2.4.2.2.2 Regulatory macrophages 
 
Regulatory macrophages arise in the later stages of adaptive immune responses, and the primary 
role for these cells is to dampen the immune response and limit inflammation266. Two signals are 
required for macrophages to induce their anti-inflammatory activity. The first signal can be one 
or more of the following: immune complexes, prostaglandins, adenosine or apoptotic cells, and 
has little or no stimulatory function on its own. However, when combined with a second signal, 
such as TNF-α or TLR agonist, the two signals induce the transformation of macrophages into 
regulatory macrophages.  
 
The main role of regulatory macrophages is immune resolution. Unlike wound-healing 
macrophages, regulatory macrophages do not contribute to the production of the extracellular 
matrix262. Instead, these cells down-regulate IL-12 production while inducing the production of 
IL-10. IL-10 is an anti-inflammatory cytokine that inhibits the production and activity of various 
pro-inflammatory cytokines267. A study demonstrated that regulatory macrophages from IL-10 
null mice fail to rescue LPS-challenged mice from lethal endotoxemia due to impaired immune 
resolution268. Like other types of macrophage populations, dysregulation of regulatory 
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macrophages can impose a detrimental effect on the host. Excess IL-10 can predispose the host to 
infection while insufficient IL-10 can result in tissue damage due to unresolved inflammation as 
seen in the mice with endotoxemia. 
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Figure 2.14. Mode of macrophage activation. Macrophages can be differentiated into different 
phenotypes depending on the stimuli. When classically activated with IFN-γ and TNF/TLR 
ligands, they are responsible for the innate immune response. When they are exposed to IL-4 or 
IL-13, they differentiate into wound-healing macrophages and are responsible for tissue repair. 
Lastly, macrophages differentiate into regulatory macrophages when stimulated with immuno-
complexes (or prostaglandins, adenosine or apoptotic cells) and TLR ligands, and they are 
responsible for immune resolution. 
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2.4.3 Alveolar macrophages 
 
2.4.3.1  Origin and Maintenance 
 
Alveolar macrophages are monocyte-derived macrophages that localize between the epithelial 
surfaces and fluid linings of the alveoli and airways. They are highly specialized macrophages 
that function primarily in lung defense against inhaled particulate matter, microbes and 
environmental toxins. In the first few days after birth, fetal monocytes are colonized in the 
airways, forming alveolar macrophages via stimulation with granulocyte macrophage colony-
stimulating factor (GM-CSF) secreted from epithelial cells in the lungs269. Alveolar macrophages 
have a high capacity for self-renewal, and local proliferation is the main means for alveolar 
macrophage to replenish themselves throughout life270. It was evident that alveolar macrophages 
were capable of replenishing themselves through proliferation when there was a partial depletion 
of alveolar macrophages during influenza infection271. Only in the case of substantial depletion of 
alveolar macrophages caused by radiation do haematopoietic stem cells-derived circulating 
monocytes contribute to alveolar macrophages repopulation270.  
 
2.4.3.2  Role of alveolar macrophages in the lungs 
 
During homeostasis, alveolar macrophages remain in a relatively quiescent state with a 
regulatory-like phenotype, with roles primarily in tissue homeostasis and resolution of 
inflammation272. They produce low levels of inflammatory cytokines and have a reduced 
phagocytic ability compared to the resident macrophages in other tissues273. Also contrary to their 
counterparts, alveolar macrophages are inefficient at inducing T cell antigen-specific response 
because they have poor antigen presenting ability as well as a lack of expression of co-
stimulatory molecules274. This is an important characteristic of alveolar macrophages so that pro-
inflammatory responses are not triggered when exposed to tissue debris or innocuous antigens. 
They also produce immunosuppressive prostaglandins and anti-inflammatory transforming 
growth factor-β1 (TGFβ1) to suppress T cell activation275. An in vivo study has demonstrated that 
mice depleted of alveolar macrophages exhibited excessive inflammation and immunity to 
innocuous antigens276.  
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The regulatory phenotype of alveolar macrophages is maintained by the lung microenvironments. 
Alveolar macrophages activation is tightly controlled through cell-cell and soluble mediator 
interactions, and the most important regulations are via interactions with OX-2 membrane 
glycoprotein (CD200) and IL-10. Alveolar macrophages express high levels of CD200R, and 
they interact with the CD200 expressed on type II alveolar epithelial cells, inhibiting the alveolar 
macrophages from pro-inflammatory activation277, 278. The regulatory phenotype of alveolar 
macrophages is also contributed by interaction with IL-10. The main sources of IL-10 are from 
healthy airway epithelium and alveolar macrophages during homeostasis279. As mentioned 
earlier, IL-10 is an anti-inflammatory cytokines that can suppress expression of pro-inflammatory 
cytokines267. This suggests that the destruction of airway epithelium or the loss of exposure to the 
regulatory ligands may direct alveolar macrophages to respond to airway antigens in a pro-
inflammatory manner. As a result, this promotes macrophages to switch into different subtypes 
(classical, wound-healing, or regulatory) depending on the stimulants. 
 
Although alveolar macrophages are essential to prevent unwanted inflammation from exposure to 
innocuous antigens, they are able to initiate strong immune responses to something more 
pathogenic.  Alveolar macrophages express a wide array of receptors that recognize pathogen-
associated molecular patterns (PAMPs) and danger-associated molecular patterns (DAMPs). 
Activation of toll-like receptor (TLR) by PAMP inhibits the IL-10R signal transduction and 
overrides the inhibitory effect of IL-10280. Once activated, alveolar macrophages display greater 
phagocytic capacity, remove T cell suppression and produce increased levels of pro-inflammatory 
cytokines281-283. Activated alveolar macrophages also drive the influx of inflammatory leukocytes 
such as neutrophils and monocytes through chemokines secretion. The importance of alveolar 
macrophages in initiating inflammatory response is illustrated by a study that reported reduced 
chemokine production and neutrophil infiltration during inflammation due to alveolar 
macrophages depletion in mice284. 
 
2.4.3.3  Alveolar macrophages in airway diseases 
 
Alveolar macrophages are one of the most important immune cells in the lungs that play a vital 
role in host defense and immune regulation during airway inflammation or infection. However, 
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they also contribute to some of the pathologies during airway diseases (Figure 2.15). Alveolar 
macrophages from CF patients displayed pro-inflammatory phenotypes and impaired 
phagocytosis ability285, and they secrete high levels of chemokines in the absence of pulmonary 
infection286. Their inefficient clearance of pathogens and persistent release of pro-inflammatory 
cytokines perpetuate inflammation in the airways and eventually lead to tissue damage in CF 
patients.  
 
Similar to CF, alveolar macrophages also contribute to the pathological lesions in COPD patients. 
As mentioned above, cigarette smoke exposure induced IL-8 expression and impaired 
efferocytosis in alveolar macrophages174, 176, resulting in persistent neutrophil infiltration in the 
airways. Together with neutrophils, alveolar macrophages secreted excess elastases and MMPs 
that contributed to structural degradation (emphysema) of the lungs176, 177. This is salient when 
depletion of alveolar macrophages prevented the development of emphysema in an experimental 
model of COPD287.  
 
In the case of asthma, alveolar macrophages are suggested to contribute to airway remodeling. 
They are differentiated into wound-healing macrophages due to the stimulation of Th2 cytokines 
in the environment. They over-express profibrotic factors and display increased biogenesis of 
polyamines and proline to facilitate fibrogenesis of the airways288, 289. Alveolar macrophages 
from asthmatic patients secrete higher levels of IL-13, which perpetuate their wound-healing 
phenotype in an autocrine manner290. However, alveolar macrophages remain vital to asthmatic 
patients as their depletion worsens airway hyper-responsiveness and inflammation in asthmatic 
models in vivo291, 292. 
 
Alveolar macrophages are like double-edge swords. They are crucial to maintain pulmonary 
homeostasis by performing anti-inflammatory functions and clearing harmful pathogens, but they 
are also an integral part of the mechanisms perpetuating inflammation and tissue injury 
associated with different airway diseases.  
 
The human hCLCA1 and its murine ortholog mCLCA3 are highly expressed from airway 
epithelial cells in airway diseases in inflammatory airway diseases in which alveolar 
macrophages are central to disease progression, such as cystic fibrosis, asthma, and COPD43, 84, 95. 
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As mentioned above, alveolar macrophages regulate the immune system in the lung by 
controlling the expression of cytokines. During airway inflammation, pro-inflammatory cytokines 
are secreted from alveolar macrophages and other immune cells to eliminate pathogens. 
However, excess pro-inflammatory cytokines often lead to prolonged inflammation that can 
result in tissue damage. Our studies demonstrated that hCLCA1 is able to positively simulate the 
expression of different pro-inflammatory cytokines in alveolar macrophages. This suggests that 
hCLCA1 is partly responsible for the cytokine response elicited by alveolar macrophages in 
airway diseases. 
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Figure 2.15. Schematic models of how alveolar macrophages play a role in airway diseases. 
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STUDY 1 – SECRETED HCLCA1 IS A SIGNALING MOLECULE THAT ACTIVATES 
AIRWAY MACROPHAGES 
 
The CLCA gene family produces both secreted and membrane-associated proteins that modulate 
ion-channel function, drive mucus production and have a poorly understood pleiotropic effect on 
airway inflammation. The primary up-regulated human CLCA ortholog in airway inflammation 
is hCLCA1. Here we show that this protein can activate airway macrophages, inducing them to 
express cytokines and to undertake a pivotal role in airway inflammation. In a U-937 airway 
macrophage–monocyte cell line, conditioned media from HEK 293 cells heterologously 
expressing hCLCA1 (with or without fetal bovine serum) increased the levels of pro-
inflammatory cytokines (IL-1β, IL-6, TNF-α and IL-8). This effect was independent of the 
metalloprotease domain of hCLCA1. Primary porcine alveolar macrophages were similarly 
activated, demonstrating the effect was not cell line dependent. Similarly, immuno-purified 
hCLCA1 at physiologically relevant concentration of ~100 pg/mL was able to activate 
macrophages and induce pro-inflammatory response. This cytokine response increased with 
higher concentration of immuno-purified hCLCA1. These findings demonstrate the ability of 
hCLCA1 to function as a signaling molecule and activate macrophages, central regulators of 
airway inflammation.  
 
 
This chapter was published as: Ching, J. C., Lobanova, L. & Loewen, M. E. (2013). Secreted 
hCLCA1 is a signaling molecule that activates airway macrophages. PLoS One 8, e83130. 
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3.1 Introduction 
 
CLCA	genes	(CL	stands	for	chloride-channel	modulating	and	CA	for	calcium-activated)	are	induced	in	airway	epithelial	cells	by	inflammation14.	This	induced	expression	often	exceeds	that	of	most	other	inflammatory	mediators293.	The	gene	products	have	a	pleiotropic	effect,	generating	secreted	and	membrane-associated	proteins	that	increase	mucus	production,	leukocyte	infiltration	and	airway	hyper-responsiveness,	with	single-nucleotide	polymorphisms	increasing	asthma	susceptibility	as	well14,	43,	92,	163,	293-295.	Although	CLCA	proteins	were	originally	identified	as	calcium	activated	chloride	channels,	we	and	others	concluded	that	they	only	modulated	channel	pores	(suggesting	a	signaling	ability)1,	4,	36,	59,	60.	How	putative	signaling	ligands	could	cause	a	seemingly	pleotropic	effect	on	airway	inflammation	was	unclear.	One	possibility	was	that	CLCAs	modified	a	central	mediator	of	airway	inflammation,	such	as	the	airway	macrophage.		Airway	macrophages	are	one	of	the	major	resident	immune	cell	types	responsible	for	lung	defense296.	How	a	macrophage	is	activated	will	determine	its	function215.	“Classically”	activated	macrophages	secrete	high	levels	of	pro-inflammatory	cytokines	(such	as	IL-8,	IL-6	and	IL-1β),	enhancing	their	microbicidal	capacity	by	producing	oxygen	and	nitrogen	free	radicals215.	“Alternatively”	activated	macrophages	secrete	high	levels	of	anti-inflammatory	cytokines	(such	as	IL-10	and	IL-12),	dampening	the	immune	response	and	promoting	wound	healing297.	Generally,	macrophage	activation	has	a	receptor-driven	signal	transduction	mechanism	requiring	activation	of	(cytoplasmic	membrane)	potassium	and	chloride	channels	to	proceed298-300.	The	primary	up-regulated	human	CLCA	ortholog	in	human	airway	inflammation	is	hCLCA1.	If	this	protein	activates	macrophages,	the	pleiotropic	effect	of	CLCA	genes	can	be	explained.		In	this	report,	we	used	a	human	monocyte	cell	line	(U-937)	and	primary	porcine	alveolar	macrophages	to	test	whether	the	secreted	form	of	hCLCA1	can	activate	macrophages.	We	also	assessed	the	role	of	the	autoproteolytic	metalloprotease	(hydrolase)	domain	of	hCLCA1,	which	contains	a	zinc-reactive	HEXXH	motif	that	cleaves	the	protein	into	a	large	~90	kDa	N-terminal	and	a	small	~40	kDa	C-terminal	fragment,	in	the	macrophage	
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activation	process68,	301.	We	found	using	progressively	purified	secreted	hCLCA1	protein,	that	it	possesses	an	intrinsic	ability	to	signal	and	activate	airway	macrophages.	This	signaling	property	was	independent	of	its	hydrolase	domain	activity.																													
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3.2 Materials and Methods 
 
3.2.1 Cell culture and transfection 
 Human	embryonic	kidney	cells	(HEK293	cell	line;	CRL1573;	ATCC)	were	grown	in	DMEM-Glutamax	medium	(10566-016;	Life	Technologies)	supplemented	with	10%	fetal	bovine	serum	(FBS;	16000-044;	Life	Technologies)	and	1%	penicillin-streptomycin	(pen-strep;	15140-122;	Life	Technologies)	at	37	°C	in	a	humidified	atmosphere	with	5%	CO2.	Cells	were	seeded	and	transfected	in	six-well	plates	with	the	vectors	pIRES2-EGFP,	wild-type	pIRES2-EGFP-hCLCA1	or	hydrolase-inactive	E157Q	mutant	pIRES2-EGFP-hCLCA1	(GenScript)	using	the	transfection	reagent	FuGENE	HD	(E2311;	Promega)	at	a	3:1	FuGENE	HD	Transfection	Reagent	to	DNA	ratio.		Human	monocytes	(U-937	cell	line;	CRL1593.2;	ATCC)	were	grown	in	RPMI-1640	medium	(SH3025502;	Thermo	Scientific)	supplemented	with	10%	heat	inactivated	FBS	and	1%	pen-strep	at	37	°C	in	a	humidified	atmosphere	with	5%	CO2.	Porcine	alveolar	macrophages	were	grown	in	RPMI-1640	medium	supplemented	with	20%	heat	inactivated	FBS	and	1%	pen-strep	at	37	°C	in	a	humidified	atmosphere	with	5%	CO2.			
3.2.2	 Media	collection,	immunoprecipitation	and	protein	concentration		
determination		At	Day	2	post-transfection,	conditioned	FBS-containing	medium	was	collected.	Conditioned	FBS-free	medium	was	collected	at	Day	3	(after	replacing	the	initial	HEK293	medium	with	FBS-free	DMEM	at	Day	2).	Macromolecules	in	the	collected	media	were	concentrated	using	Amicon	Ultra-15	Centrifugal	Filter	Units	(UFC903008;	EMD	Millipore).	The	concentrations	of	the	proteins	were	determined	using	a	Bradford	protein	assay	(500-0201;	Bio-rad)	Conditioned	FBS-free	hCLCA1	and	FBS-free	eGFP	macromolecule	samples	were	immunoprecipitated	with	a	Pierce	Crosslink	Magnetic	IP/Co-IP	Kit	(88805;	Thermo	Scientific)	using	hCLCA1-N14	antibody	(sc-46866;	Santa	Cruz)	according	to	manufacturers’	
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protocols.	To	improve	the	yield	of	the	immunoprecipitation,	we	increased:	the	antibody	amount	used	in	the	antibody	coupling	step	to	8	μg	from	5	μg,	the	antibody	coupling	time	to	30	minutes	from	15	minutes,	and	the	sample	incubation	time	to	1.5	h	from	1	h.	The	concentration	of	the	immunoprecipitated	hCLCA1	protein	was	determined	from	a	standard	curve	generated	using	a	2-fold	dilution	series	of	lysozyme	(L-6876;	Sigma-Aldrich)	on	a	silver	stained	SDS-PAGE	gel.	The	concentrations	of	lysozyme	used	in	the	standard	curve	were	100	pg/μL,	50	pg/μL,	25	pg/μL,	12.5	pg/μL,	6.25	pg/μL,	and	3.125	pg/μL.		
3.2.3	 Monocyte	differentiation	and	activation		Monocyte	cells	were	seeded	in	each	well	(1.3×106	to	1.5×106	cells/well)	in	a	6-well	plate	and	differentiated	into	macrophages	with	0.1	nM	phorbol-12-myristate-13-acetate	(PMA;	P8139;	Sigma-Aldrich)	in	supplemented	FBS-free	RPMI-1640	medium	for	18	h.	The	cells	were	washed	2	times	with	FBS-free	RPMI-1640	medium	and	incubated	in	supplemented	RPMI-1640	media	containing	3,	6	or	10%	FBS.	In	the	conditioned	FBS-containing	medium	experiment,	0.1,	1	or	10	mg/mL	of	eGFP	or	hCLCA1	was	added	to	macrophages	in	10%	FBS	growth	medium.	In	conditioned	FBS-free	medium	experiment,	66.7	μg/mL	or	200.0	μg/mL	of	eGFP	or	hCLCA1	was	added	to	macrophages	in	3,	6,	or	10%	FBS	growth	medium	to	determine	optimal	FBS	concentration;	and	3.3	μg/mL,	16.7	μg/mL	or	33.3	μg/mL	of	hCLCA1	was	added	to	macrophages	in	6%	FBS	growth	medium	to	determine	the	dose	response.	In	a	further	experiment,	45	μL	of	immuno-purified	hCLCA1	(93.3	pg/mL	or	141.7	pg/mL)	or	45	μL	of	control	(immunoprecipitation	of	eGFP	using	hCLCA1-N14	antibody)	were	added	and	incubated	in	6%	FBS	growth	medium	for	24	h	or	48	h.		
3.2.4	 SDS-PAGE	and	western	blot	Analysis	
	Cell	lysates	were	collected	using	M-PER	mammalian	protein	extraction	reagent	(78503;	Thermo	Scientific)	with	the	addition	of	Halt	protease	and	phosphatase	inhibitor	cocktail	(78440;	Thermo	Scientific).	The	samples	(cell	lysates	or	media)	were	boiled	in	2x	denaturing	buffer	(20%	glycerol,	4%	SDS,	125mM	Tris	pH	6.8,	0.3mM	bromophenol	blue)	and	10%	β-mercaptoethanol	(BME;	M6250;	Sigma-Aldrich),	and	they	were	analyzed	by	
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10%	or	12%	SDS-PAGE.		The	SDS-PAGE	gel	was	stained	with	coomassie	blue	stain	(staining	–	45%	methanol,	10%	glacial	acetic	acid,	45%	water,	3g/L	Coomassie	Brilliant	Blue	R250;	destaining	–	20%	methanol,	10%	glacial	acetic	acid,	70%	water)	and	a	Pierce	Color	Silver	Stain	Kit	(24597;	Thermo	Scientific)	according	to	manufacturers’	protocols.		Densitometry	was	performed	using	a	ChemiDoc	MP	System	(170-8280;	Bio-rad).		For	western	blot	analysis,	proteins	were	electroblotted	onto	PVDF	membrane	(RPN303LFP;	GE	Healthcare	Life	Sciences)	with	transfer	buffer	(25mM	Tris,	192mM	glycine,	20%	methanol).		Membranes	were	blocked	overnight	at	4	°C	with	5%	bovine	serum	albumin	in	PBST	buffer	(137mM	NaCl,	2.6mM	KCl,	1.5mM	KH2PO4,	8.1mM	Na2HPO4,	0.1%	Tween-20;	Sigma-Aldrich)	and	subsequently	probed	for	2	h	at	room	temperature	with	primary	antibodies	in	PBST.	The	membranes	were	then	incubated	for	1	h	at	room	temperature	with	secondary	antibodies	in	PBST.	Proteins	were	detected	and	analyzed	using	Typhoon	Trio	and	ImageQuant	TL	system	(63005583;	GE	healthcare	Life	Sciences).	Densitometry	analysis	of	intracellular	IL-1β	protein	was	normalized	to	GAPDH	in	each	sample	as	previously	described302,	303.	The	primary	antibodies	used	were	hCLCA1	(N-14;	sc-46866;	Santa	Cruz),	GAPDH	(FL-335;	sc-25778;	Santa	Cruz),	IL-1β	(H-153;	sc-7884;	Santa	Cruz),	and	GAPDH	(MAB374;	EMD	Millipore).	The	secondary	antibodies	used	were	Alexa	Fluor	488	Donkey	anti-Goat	IgG	antibody	(A11055;	Life	Technologies),	ECL	Plex	Goat	anti-Mouse	IgG-Cy5	antibody	(PA45009;	Amersham	Biosciences),	and	DyLight	488	conjugate	Goat	anti-Rabbit	IgG	antibody	(35552;	Thermo	Scientific).		
3.2.5	 Bio-Plex	suspension	array	system	
	After	48	h	activation	with	immuno-purified	proteins,	macrophage	medium	was	collected	and	analyzed	for	cytokine	levels	using	Bio-Plex	Suspension	Array	System	(171-000201;	Bio-rad)	according	to	the	manufacturers’	protocols.	The	Bio-Plex	Pro	Human	Cytokine	8-plex	Assay	(M50-000007A;	Bio-rad)	we	used	included	the	following	cytokines:	IL-2,	IL-4,	IL-6,	IL-8,	IL-10,	GM-CSF,	IFN-γ,	and	TNF-α.					
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3.2.6	 RNA	isolation	and	real-time	quantitative	PCR		For	macrophages	activated	in	FBS-containing	media,	RNA	was	extracted	after	1,	2,	4,	6,	12	and	24	h	using	TRIzol	Reagent	(15596018;	Life	Technologies)	according	to	manufacturers’	protocols.	For	macrophages	activated	in	FBS-free	media,	RNA	was	extracted	after	24	h.	For	macrophages	activated	with	immunoprecipitated	proteins,	RNA	was	extracted	after	24	or	48	h.	The	collected	RNA	was	analyzed	with	a	GoTaq	2-Step	RT-qPCR	system	(A6010;	Promega)	and	Mx3005P	real-time	PCR	machine	(401514;	Agilent).	cDNA	of	each	sample	was	measured	in	duplicates	in	Mx3005P	real-time	qPCR	machine,	and	the	average	CT	(cycle	threshold)	value	was	used	to	calculate	the	fold	difference	of	each	gene.	Human	primers	were	designed	for	GAPDH,	TNF-α,	IL-12a,	IL-8,	IL-1β,	IL-6	and	IL-10;	and	porcine	primers	were	designed	for	NADH	dehydrogenase,	TNF-α,	IL-12a,	IL-8,	IL-1β,	IL-6	and	IL-10	(Table	3.1).	hGAPDH	and	pNADH	were	used	as	the	reference	genes	for	analysis.		
3.2.7	 Porcine	alveolar	macrophage	isolation		A	solution	of	100	mL	of	0.1	M	PBS+	(supplemented	with	1%	pen-strep	and	1x	antibiotic-antimycotic	(15240112;	Life	Technologies))	was	injected	into	porcine	lungs.	The	lungs	were	obtained	with	specific	permission	for	use	in	this	study	from	a	local	federally	inspected	abattoir	(Friesen's	Meat	Processing,	Warman,	SK).	Lung	lavage	fluid	was	collected	and	filtered	through	70	μm	cell	strainers	(352350;	Corning).	The	filtered	cells	were	subjected	to	repeated	centrifugation	at	400g	for	10	min	at	4	°C	and	washed	with	20	mL	1.0	M	PBS+,	2–3	mL	of	erythrocyte	lysing	solution	(155mM	NH4Cl,	10mM	NaHCO3,	1mM	EDTA,	pH	7.4	with	HCl)	for	20	s,	45	mL	of	1.0	M	PBS+	and	then	25	mL	of	1.0	M	PBS+.	The	pelleted	cells	were	subsequently	re-suspended	in	culture	medium	(RPMI-1640	with	20%	heat-inactivated	FBS,	1%	pen-strep	and	1x	antibiotic-antimycotic).	The	cells	were	counted	using	trypan	blue	(15250061;	Life	Technologies),	and	1.5×107	cells/mL	were	cryopreserved	in	liquid	nitrogen	using	culture	medium	with	10%	DMSO.				
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3.2.8	 Porcine	alveolar	macrophage	stimulation		A	total	of	1.5×107	cells	were	thawed	at	37	°C,	added	to	8	mL	warm	culture	medium	and	centrifuged	at	500g	for	5	min.	The	cells	were	then	re-suspended,	and	1.5×107	cells	were	seeded	in	each	well	of	a	six-well	plate	with	3	mL	of	culture	medium	in	each	well.	The	plates	were	incubated	15–18	h	at	37	°C	under	a	humidified	5%	CO2	atmosphere.	The	cells	were	washed	2	times	with	culture	medium	and	incubated	in	3	mL	culture	medium.	To	activate	the	porcine	alveolar	macrophages,	66.7	µg/mL,	200	µg/mL	or	1000	µg/mL	of	eGFP	or	hCLCA1	in	FBS-free	medium	was	added.		
3.2.9	 Efficiency	and	fold	difference	calculations		Dilution	series	from	1×100-fold	to	1×10−5-fold	of	cDNA	were	used	to	determine	the	primer	efficiency.	The	CT	value	obtained	in	each	dilution	was	used	to	generate	a	linear	plot	of	CT	vs.	log	copies.	The	efficiency	of	the	primer	set	was	determined	with	the	equation	Eff	=	10(−1/slope).	The	fold	difference	between	hCLCA1-	and	eGFP-activated	samples	was	determined	using	an	efficiency-corrected	calculation	with	eGFP-activated	macrophage	serving	as	control	and	hGAPDH	or	pNADH	serving	as	the	reference	gene304:		 ( ) ( ) ( ) ( )T, target T, refMean control  Mean sample Mean control  Mean sampletarget ref/C Cratio Eff EffΔ − Δ −= 		
3.2.10	Statistics		All	data	are	expressed	as	means	±	standard	error	of	the	mean	(SEM).	Each	biological	replicate	was	a	result	of	an	individual	transfection	paired	with	an	eGFP	transfection.	Each	biological	replicate	was	performed	on	different	days.	Fold	differences	were	calculated	by	comparing	hCLCA1-activated	macrophage	to	its	paired	eGFP-activated	macrophage	control.	The	normality	test	was	done	using	Shaprio-Wilk	test,	and	the	fold	difference	values	of	RT-qPCR	and	Bio-Plex	assay	were	analyzed	using	Kruskal-Wallis	one-way	analysis	of	variance	test	with	Conover-Inman	test.	Friedman	two-way	analysis	of	variance	was	performed	to	compare	the	fold	difference	of	mRNA	expression	between	groups	(time,	wild	type	hCLCA1	
	 82	
vs.	mutant	hCLCA1,	concentration,	etc.).	All	western	blot	data	was	normalized	to	the	appropriate	controls,	and	each	western	blot	was	a	result	of	an	individual	biological	replicate.	One-way	t-tests	were	performed	with	the	mean	set	as	1305,	306.	Significance	was	determined	at	p	<	0.05.			
3.2.11	Ethics	Statement	
	Obtaining	and	use	of	animal	tissue	was	specifically	approved	for	this	study	by	the	University	of	Saskatchewan’s	Institutional	Animal	Care	and	Use	Committee	(IACUC)	Permit	#	20120100.	
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Table 3.1. Primers used in RT-qPCR experiments. 
Human qPCR Primers 
Gene 
Name 
 
Forward Primers (5′ à  3′) 
 
Reverse Primers (5′ à  3′) 
GAPDH CAAGGTCATCCATGACAACTTTG GGGCCATCCACAGTCTTCTG 
TNF-α TGCTGCACTTTGGAGTGATCG TGCTACAACATGGGCTACAGG 
IL-12a CAGTGGAGGCCTGTTTACCATTG TACTACTAAGGCACAGGGCCATC 
IL-8 TCTCTTGGCAGCCTTCCTGATTTC ATTTCTGTGTTGGCGCAGTGTG 
IL-1β GCTGATGGCCCTAAACAGATG TGTAGTGGTGGTCGGAGATTC 
IL-6 AGCCACTCACCTCTTCAGAAC GTGCCTCTTTGCTGCTTTCAC 
IL-10 AAGCTGAGAACCAAGACCCAGACA AAAGGCATTCTTCACCTGCTCCAC 
Porcine qPCR Primers 
Gene 
Name 
 
Forward Primers 
 
Reverse Primers 
NADH TCATCGGGGCCCTACGAGCA GGCGAAAGGTCCGGCTGCAT 
TNF-α ACGCTCTTCTGCCTACTGCACTTC TCCCTCGGCTTTGACATTGGCTAC 
IL-12a CCACTTGAACTAGCCACGAATGAG AGATACTGCTAAGGCACAGGGTTG 
IL-8 AGGACCAGAGCCAGGAAGAGAC CTTGCCAGAACTGCAGCCTCAC 
IL-1β CTCCAGCCAGTCTTCATTGTTCAG GTTGTCACCGTAGTTAGCCATCAC 
IL-6 CCAATCTGGGTTCAATCAGGAGAC CAGCCTCGACATTTCCCTTATTGC 
IL-10 AAGACGTAATGCCGAAGGCAGAGA TGCTAAAGGCACTCTTCACCTCCT 
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3.3 Results 
 
3.3.1 Response of the U-937 macrophage cell line to FBS-containing hLCCA1 medium 
 
The activation of macrophages by secreted hCLCA1 was investigated using the U-937 
macrophage cell line treated with conditioned FBS-containing medium from HEK293 cells 
heterologously expressing hCLCA1 or eGFP. Macrophage activation was demonstrated by 
expression of the pro-inflammatory cytokines IL-8, IL-6, IL-1β and TNF-α (Figure 3.1). The 
presence of secreted hCLCA1 in the medium was confirmed by western blot analysis (Figure 
3.2). There was more cleaved hCLCA1 product than the hCLCA1 precursor present in both wild-
type hCLCA1 lysate and medium, whereas, E157Q hydrolase-inactive hCLCA1 had only the 
precursor present. Densitometry analysis showed that there was no significant difference between 
the expression of wild-type hCLCA1 and E157Q mutant hCLCA1 in medium (Figure 3.2). In a 
log-scale dose test from 0.1 mg/mL to 10 mg/mL of total protein from the conditioned medium, 
the strongest response for these cytokines was obtained at 1 mg/mL (Figure 3.1). Concentrated 
pure medium and conditioned medium from HEK293 cells expressing the large protein 
TMEM16A (tested as an additional control) was found to cause no significant activation 
(Figure 3.1). At the optimized dose of 1 mg/mL, the expression of IL-8, IL-6, IL-1β and TNF-α 
in response to wild-type hCLCA1 and its hydrolase-inactive E157Q mutant was followed over 
24 h (Figure 3.3); this test revealed no difference in the mRNA expression between E157Q and 
wild-type hCLCA1-activated macrophages. Generally, the longer the macrophages were 
incubated with hCLCA1, the higher the activation (Figure 3.3). Lipopolysaccharide (LPS), a 
potent endotoxin that activates through toll-like receptor 4, was used as a positive control and 
produced a similar time-dependent activation. 
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Figure 3.1. Conditioned FBS-containing hCLCA1 medium shows dose-dependent effect. 
Macrophages were activated for 24 h with 0.1 mg/mL, 1.0 mg/mL, or 10 mg/mL of FBS-
containing stimulants (eGFP, wild-type hCLCA1, E157Q mutant hCLCA1, 1.0 mg/mL pure 
media, or 1.0 mg/mL TMEM16A). Dose-dependent cytokine mRNA expression by macrophages 
was quantified through RT-qPCR. The fold difference at each condition was compared against 
eGFP (the control) of the same concentration. Results were presented as the means of 3 samples 
± SEM. Each sample was a result of an individual transfection paired with an eGFP transfection. 
Significant fold differences from corresponding control values (eGFP of the same concentration) 
are indicated by * (p < 0.05), ** (p < 0.005) or *** (p < 0.001). 
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Figure 3.2. Representative western blot image of eGFP- and hCLCA1-transfected HEK-293 
cell lysates and media using hCLCA1 N-terminal antibody. Both precursor and N-terminal 
hCLCA1 products were secreted into the extracellular space. However, there was a higher 
proportion of cleaved product than precursor in the wild-type hCLCA1 lysate and medium. 
Relative protein expressions of secreted wild-type and secreted E157Q mutant hCLCA1 were 
compared using densitometry (the secreted E157Q mutant hCLCA1 was normalized to the 
secreted wild-type hCLCA1 in each sample). No statistical significant difference was found 
between the protein levels of wild-type andE157Q mutant hCLCA1 in the medium. Wild-type 
hCLCA1 included 125 kDa uncleaved precursor and 90kDa cleaved N-terminal hCLCA1, while 
E157Q mutant hCLCA1 only included 125kDa uncleaved precursor hCLCA1. Results were 
presented as the means of 3 samples ± SEM. 
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Figure 3.3. Conditioned FBS-containing hCLCA1 medium shows time-dependent effect. 
Macrophages were activated with 1.0 µg/mL LPS, 1.0 mg/mL FBS-containing wild-type 
hCLCA1, E157Q mutant hCLCA1 or eGFP medium. Time-dependent (1, 2, 4, 6, 12, 24 h) 
cytokine mRNA expression by macrophages was quantified through RT-qPCR. The fold 
difference at each condition was compared against eGFP (the control) of the same condition. 
Results were the means of 4 samples ± SEM. Each sample was a result of an individual 
transfection paired with an eGFP transfection. Significant fold differences from the 
corresponding control values (eGFP of the same concentration) are indicated by * (p < 0.05), ** 
(p < 0.005) or *** (p < 0.001). 
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3.3.2 Dose response of the U-937 cell line to FBS-free conditioned hCLCA1 medium  
 
The macrophage growth medium for the dose response experiment was supplemented to the 
optimized concentration of 6% FBS, as determined by cytokine response (Figure 3.4). An 
appropriate FBS concentration was essential for macrophage growth and activation. The 
expression of hCLCA1 was confirmed by western blot (Figure 3.5A). Comparing between the 
FBS-containing medium and FBS-free medium, both western blot and coomassie gel (Figure 
3.5B) staining showed that there was significantly less impurities in the FBS-free medium 
(Figure 3.5). The dose effect of conditioned FBS-free hCLCA1-containing medium on 
macrophage activation was carried out to eliminate any effects of FBS in the FBS-containing 
hCLCA1 medium (Figure 3.6). The concentration of total secreted protein in the medium used in 
Figure 3.1 was estimated to be between 50 and 200 µg/mL because we estimated that hCLCA1 
only made up of ~1% of the total protein in the FBS-containing conditioned medium from 
coomassie stained gel. Therefore, concentrations of FBS-free hCLCA1 medium ranging from 
3.3 µg/mL to 200 µg/mL were used for the macrophage activation dose response test, in which 
66.7 µg/mL of FBS-free hCLCA1 medium was found to provide the maximum increase in the 
expression of IL-8, IL-6, and IL-1β; conversely, 200 µg/mL of FBS-free hCLCA1 medium 
caused a significant decrease in the anti-inflammatory cytokine IL-10 (Figure 3.6). The level of 
IL-12a never responded significantly and was generally just at the level of detection (Figure 3.6).  
	 89	
 
Figure 3.4. 6% FBS is determined to be the optimal FBS % in growth medium to activate 
macrophages. U-937 macrophage cells were activated for 24 h using 66.7 µg/mL or 200 µg/mL 
of FBS-free eGFP medium or FBS-free wild-type hCLCA1 medium with 3%, 6%, or 10% FBS 
growth medium. IL-8, IL-6, IL-1β, TNF-α, IL-12a and IL-10 were quantified by their mRNA 
expression using RT-qPCR. The fold difference at each concentration was compared against 
eGFP (the control) at the same concentration. Results were the means of 5 samples ± SEM. Each 
sample was a result of an individual transfection paired with an eGFP transfection. Significant 
fold differences from corresponding control values (eGFP of the same concentration) are 
indicated by *  (p < 0.05), ** (p < 0.005) or *** (p < 0.001). 
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Figure 3.5. Representative western blot and coomassie gel showing FBS-containing and 
FBS-free conditioned media. (A) Western blot analysis probing against hCLCA1 N-terminal 
antibody was utilized in conjunction with (B) Coomassie gel staining to compare the total protein 
contents between FBS-containing hCLCA1 medium and FBS-free hCLCA1 medium. Both 
western blot and coomassie gel staining showed that hCLCA1 was one of the major secreted 
molecules, and there was less impurities in the FBS-free hCLCA1 medium without a major loss 
in hCLCA1 protein.   
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Figure 3.6. Conditioned FBS-free hCLCA1 medium shows a dose-dependent effect. U-937 
macrophages were activated for 24 h using 3.3 µg/mL, 16.7 µg/mL, 33.3 µg/mL, 66.7 µg/mL, or 
200 µg/mL of FBS-free wild-type hCLCA1 medium or FBS-free eGFP medium in 6% FBS 
growth medium. IL-8, IL-6, IL-1β, TNF-α, IL-12a and IL-10 were quantified by their mRNA 
expression using RT-qPCR.  The fold difference at each concentration was compared against 
eGFP (the control) at the same concentration.  Results were the means of 5 samples ± SEM. Each 
sample was a result of an individual transfection paired with an eGFP transfection. Significant 
fold differences from corresponding control values (eGFP of the same concentration) are 
indicated by * (p < 0.05), ** (p < 0.005) or *** (p < 0.001). 
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3.3.3 Activation of primary porcine macrophage by hCLCA1 
 
To confirm that the effect of hCLCA1 was not specific to the U-937 cell line, isolated porcine 
alveolar macrophages were tested with FBS-free hCLCA1 or eGFP medium. Activation by 
hCLCA1 was observed in 20% FBS medium, a standard growth condition for isolated porcine 
macrophages (Figure 3.7). However, 66.7 µg/mL of FBS-free hCLCA1 medium activated only 
IL-1β; 200 µg/mL of FBS-free hCLCA1 medium was required to increase most of the pro-
inflammatory cytokines (including TNF-α, IL-8, IL- 6 and IL-1β). At 1000 µg/mL FBS-free 
hCLCA1 medium, however, the pro-inflammatory response was reduced. 
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Figure 3.7. Activation of porcine alveolar macrophages with hCLCA1. Porcine alveolar 
macrophages were activated with different concentrations (66.7 µg/mL, 200 µg/mL or 
1000 µg/mL) of FBS-free eGFP medium or FBS-free wild-type hCLCA1 medium. IL-8, IL-6, 
IL-1β, TNF-α, IL-12a and IL-10 were quantified by their mRNA expression using RT-qPCR. 
The fold difference at each concentration was compared against eGFP (the control) at the same 
concentration. Results were the means of 7 samples ± SEM. Each sample was a result of an 
individual transfection paired with an eGFP transfection. Significant fold differences from 
corresponding control values (eGFP of the same concentration) are indicated by * (p < 0.05), ** 
(p < 0.005) or *** (p < 0.001). 
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3.3.4	 Activation	of	the	U-937	cell	line	by	immuno-purified	hCLCA1	
	To	demonstrate	that	hCLCA1	was	acting	on	its	own	and	not	in	conjunction	with	other	components	secreted	by	the	HEK293	cell	line,	immuno-purified	hCLCA1	from	FBS-free	medium	was	tested.	The	presence	and	purity	of	hCLCA1	was	confirmed	with	western	blot	and	silver	stain	(Figure	3.8A).	Since	the	concentration	of	immuno-purified	hCLCA1	was	beyond	the	detection	range	of	Bradford	protein	assay	(>	1	μg/mL),	we	measured	the	concentration	of	hCLCA1	using	a	standard	curve	generated	by	a	2-fold	dilution	series	of	lysozyme	on	a	silver	stained	SDS-PAGE	gel	(Figure	3.8B).	Densitometry	analysis	showed	that	the	concentration	of	immuno-purified	hCLCA1	was	6.2	±	0.3	pg/μL	(Figure	3.8B).	Therefore,	the	maximum	hCLCA1	concentration	achievable	for	macrophage	activation	was	93.3	pg/mL.	Macrophages	stimulated	with	93.3	pg/mL	of	pure	hCLCA1	activated	similarly	to	that	induced	by	the	conditioned	FBS-free	medium	after	48	h,	although	only	IL-1β	levels	were	enhanced	after	24	h	(Figure	3.9).	
	To	demonstrate	that	higher	concentration	of	pure	hCLCA1	can	elicit	a	stronger	effect	on	macrophages,	we	optimized	the	immune-precipitation	protocol	to	yield	a	higher	hCLCA1	concentration.	The	improvement	resulted	in	the	concentration	of	immuno-purified	hCLCA1	as	determined	through	densitometry	analysis	on	a	silver	stained	SDS-PAGE	gel	to	be	9.4	±	0.3	pg/μL	(Figure	3.10).	This	allowed	macrophages	to	be	activated	with	a	maximum	concentration	of	141.7	pg/mL	immuno-purified	hCLCA1	for	48	h.	Enhanced	mRNA	expression	of	pro-inflammatory	cytokines	was	observed	with	increased	hCLCA1	concentration	(Figure	3.11A).	For	example,	mRNA	expression	levels	of	IL-1β	increased	significantly	from	0.178	log	folds	to	0.317	log	folds	(p	<	0.05)	with	the	increase	in	hCLCA1	concentration	(Figure	3.9	and	3.11A).			The	increase	in	cytokine	mRNA	expression	mentioned	above	was	translated	into	an	elevated	cytokine	protein	levels.	Western	blot	and	densitometry	analysis	showed	that	intracellular	IL-1β	protein	levels	increased	by	2.38	±	0.21	folds	(p	<	0.001)	over	the	control	(Figure	3.11B).	However,	neither	LPS	nor	hCLCA1-activated	macrophages	produced	detectable	extracellular	IL-1β	protein	in	the	medium	according	to	western	blot	analysis	
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(data	not	shown).	This	suggests	that	IL-1β	release	is	dependent	on	factors	other	than	activation	in	this	cell	line.	We	then	used	a	Bio-Plex	suspension	array	system	to	measure	the	extracellular	cytokine	protein	expression	levels	in	the	medium	of	control	immuno-purified	eGFP-	and	hCLCA1-activated	macrophage.	Significant	fold	increase	over	control	protein	levels	of	IL-6	and	IL-8	was	observed,	while	IL-4,	IL-10,	GM-CSF,	IFN-γ,	and	TNF-α	protein	levels	did	not	change	significantly;	and	IL-2	was	beyond	the	detection	limit	(Figure	3.11C).				
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Figure 3.8. Representative western blot and silver stained gel on immuno-purified 
hCLCA1. (A) Western blot analysis of immuno-purified hCLCA1 and eGFP using hCLCA1 N-
terminal antibody; and silver stained acrylamide gel containing immuno-purified hCLCA1 and 
eGFP. (B) Using a standard curve generated from a 2-fold dilution series of lysozyme on a silver 
stained SDS-PAGE gel, immuno-purified hCLCA1 was determined to be 6.225 ± 0.307 pg/µL. 
Result was presented as the mean of 3 samples ± SEM. 
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Figure 3.9. Activation of macrophages with immuno-purified hCLCA1. The mRNA 
expression of cytokines in macrophages stimulated with immuno-purified hCLCA1 for 24 h and 
48 h were quantified using RT-qPCR. The fold difference was calculated against the 
corresponding control (immunoprecipitation of eGFP using hCLCA1-N14 antibody). Results for 
and were presented as the means of 10 samples ± SEM. Each sample was a result of an individual 
transfection paired with an eGFP transfection. Significant fold differences from corresponding 
control values (immuno-purified eGFP) are indicated by * (p < 0.05), ** (p < 0.005) and 
*** (p < 0.001).  
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Figure 3.10. Representative silver stained SDS-PAGE gel showing immuno-purified 
hCLCA1 with optimized protocol and a 2-fold dilution series of lysozyme. Densitometry 
analysis using lysozyme standard curve demonstrated a higher concentration of pure hCLCA1 
(9.425 ± 0.335 pg/µL) was immunoprecipitated with an optimized protocol. The optimized 
protocol yield a ~50% increase in protein amount compared to the original protocol. Result was 
presented as the mean of 3 samples ± SEM. 
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Figure 3.11. Enhanced macrophage activation with higher concentration of immuno-
purified hCLCA1. (A) The mRNA expression of cytokines in macrophages stimulated with 
141.7 pg/mL of hCLCA1 for 48 h was quantified using RT-qPCR. The fold difference was 
calculated against the corresponding control (immunoprecipitation of eGFP using hCLCA1-N14 
antibody). Results were presented as the means of 4 samples ± SEM. (B) Representative Western 
blots showing intracellular IL-1β and GAPDH levels in immuno-purified eGFP or hCLCA1-
stimulated macrophages. GAPDH was used as a loading control for densitometry analysis. 
Immuno-purified hCLCA1-stimulated macrophages had a 2.38 ± 0.21 folds increase in IL-1β 
protein levels over immuno-purified eGFP-stimulated macrophages (the hCLCA1-induced IL-1β 
was normalized to the eGFP-induced IL-1β in each sample). Results were presented as the means 
of 7 samples ± SEM. (C) Secreted cytokine protein expression in macrophages stimulated with a 
higher concentration of immuno-purified hCLCA1 was analyzed using Bio-plex Suspension 
Array System. The fold difference of each sample was compared against the corresponding 
control. Results were the means of 3 samples ± SEM. Significant fold differences from 
corresponding control values are indicated by * (p < 0.05), ** (p < 0.005) and *** (p < 0.001). 
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3.4	 Discussion	
	The	results	demonstrate	that	secreted	hCLCA1	is	able	to	function	as	a	signaling	molecule	by	activating	both	cell-line	and	primary	porcine	alveolar	macrophages	in	a	dose-	and	time-dependent	manner.	Confirmation	of	the	function	of	hCLCA1	as	a	signaling	ligand	for	airway	macrophages	can	begin	to	explain	its	pleiotropic	effects294.		
3.4.1	 Type	of	response		The	signaling	function	was	initially	demonstrated	using	conditioned	FBS-containing	medium	from	HEK293	cells	heterologously	expressing	hCLCA1.	At	an	optimal	dose	of	1	mg/mL,	the	conditioned	FBS-containing	medium	activated	macrophages	over	time	similarly	to	the	effect	of	LPS	(Figure	3.3).	To	stimulate	macrophages	without	drastically	changing	the	ionic	and	nutrient	composition	of	the	medium,	the	protein	was	concentrated	out	of	the	conditioned	medium.	However,	this	procedure	also	concentrated	the	FBS,	which	could	have	been	deleterious	to	the	macrophages	at	concentrations	of	10	mg/mL,	reducing	the	pro-inflammatory	response	(Figure	3.1).	Alternatively,	the	high	concentrations	of	FBS	and	hCLCA1	together	could	turn	off	the	pro-inflammatory	response.		Interestingly,	activating	the	macrophages	with	FBS-free	hCLCA1	at	higher	concentrations	of	FBS	(10%)	in	the	growth	media	resulted	in	only	a	slight	to	moderate	decrease	in	the	pro-inflammatory	response	(Figure	3.4).	This	decrease	was	not	as	significant	as	that	of	the	10	mg/mL	(concentrated)	hCLCA1	in	FBS-containing	medium	(Figure	3.1).	This	difference	suggests	that	a	high	concentration	of	hCLCA1	itself	may	actually	begin	to	dampen	the	pro-inflammatory	response,	a	trend	that	was	seen	with	FBS-free	hCLCA1-conditioned	medium	when	applied	to	a	macrophage	cell	line	(Figure	3.6).	Evidence	for	higher	concentrations	of	hCLCA1	having	a	reduced	pro-inflammatory	response	was	salient	in	the	porcine	alveolar	macrophage	experiment,	where	the	strong	pro-inflammatory	response	induced	by	low	concentrations	of	FBS-free	hCLCA1-containing	medium	was	lost	at	higher	concentrations	(Figure	3.7).	
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Together,	these	results	demonstrate	that	hCLCA1-containing	medium	has	the	capacity	to	induce	a	pro-inflammatory	response	that	is	dependent	on	its	concentration,	and	the	effect	of	activation	is	not	cell-line	dependent.	In	addition,	these	results	also	illustrated	hCLCA1’s	ability	to	activate	macrophages	within	a	mixed	milieu	of	macromolecules.	A	strong	pro-inflammatory	response	was	observed	when	macrophages	were	activated	with	1	mg/mL	of	FBS-containing	hCLCA1	conditioned	medium	(Figure	3.1).	The	FBS-containing	hCLCA1	conditioned	medium	is	comprised	of	a	large	number	of	immuno-reactive	factors	such	as	cytokines	or	growth	factors.	In	pathophysiological	settings,	hCLCA1	would	also	have	to	function	in	such	an	environment	of	macromolecules	and	immuno-reactive	factors	presented	in	the	BAL	fluid	of	inflamed	airways307.		
3.4.2	 Macrophage	activation	by	pure	hCLCA1		To	confirm	that	macrophage	activation	is	not	dependent	on	constituents	that	might	potentially	be	induced	and	secreted	by	hCLCA1	in	HEK293	cells,	we	immunoprecipitated	hCLCA1	from	FBS-free	hCLCA1-containing	medium.	In	the	initial	experiment	in	which	93.3	pg/mL	of	hCLCA1	was	used	to	activate	macrophages,	the	response	was	limited	to	IL-1β	in	the	first	24	h.	Up	to	48	h	of	macrophage	activation	was	required	for	IL-8	to	increase	significantly	as	well	(Figure	3.9).	It	should	be	noted	that	93.3	pg/mL	of	hCLCA1	is	lower	than	the	physiological	concentration	secreted	from	human	airway	epithelial	cells41,	thus	a	weak	response	was	expected.	However,	increasing	the	dose	to	141.7	pg/mL	of	hCLCA1	elicited	a	stronger	cytokine	mRNA	expression	in	macrophages	at	48	h	(Figure	3.11A),	demonstrating	pure	hCLCA1’s	ability	to	function	in	a	dose	dependent	manner.	This	increase	in	cytokine	mRNA	expression	was	sufficient	to	increase	cytokine	protein	expression,	further	supporting	the	physiological	relevance	of	these	findings	(Figure	3.11B	and	3.11C).	In	fact,	the	concentration	of	hCLCA1	employed	in	this	study	is	similar	to	physiological	concentrations	of	signaling	molecules	found	in	inflamed	airway,	as	many	cytokines	are	expressed	in	the	pg/mL	to	ng/mL	range	in	bronchoalveolar	lavage	(BAL)	fluid	in	asthmatic	patients307-309.				
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3.4.3	 Potential	activation	mechanisms		Taken	together,	these	findings	indicate	that	airway	macrophage	activation	is	an	intrinsic	property	of	hCLCA1.	hCLCA1	can	elicit	a	concentration-dependent	macrophage	activation.	Generally,	activation	of	pro-inflammatory	response	has	a	receptor-driven	signal	transduction	mechanism	and	is	dependent	on	ion-channel	activation	at	the	cell	surface298,	300.		The	protein	hCLCA1	could	also	activate	macrophages	by	ion-channel	modulation.	The	ability	of	CLCA	proteins	to	modulate	multiple	ion-channel	types	has	been	well-documented59,	60,	310.	These	proteins	increase	single-channel	conductance	and	directly	interact	with	channel	subunits36,	311.	However,	inhibiting	the	hydrolase	domain	of	CLCA	proteins	inhibited	their	capability	to	modulate	calcium-activated	chloride	channels	(CaCCs)70.	Our	findings	suggest	that	since	the	hydrolase-inactive	mutant	could	activate	macrophages,	then	the	CaCC-modulating	ability	of	hCLCA1	is	not	involved	in	macrophage	activation.	However,	such	results	would	not	preclude	hCLCA1	being	the	modulator	of	other	channels	that	are	independent	of	its	hydrolase	domain.	HCLCA1’s	Von	Willebrand	Factor-A	(VWA)	domain	could	for	example	act	as	a	ligand	to	modulate	ion	channels.	Such	precedents	exist	as	the	α2δ	subunit	of	the	voltage	gated	calcium	channel	modulates	its	function	by	binding	to	an	extracellular	region	of	the	channel	pore	subunit	via	its	VWA	domain	and	modifies	its	function74.			Alternatively,	hCLCA1	macrophage	activation	may	occur	through	a	signal	transduction	mechanism	driven	by	a	receptor	ligand.	Precedents	exist,	as	some	CLCA	homologs	contain	novel	integrin	binding	motifs49,	312.	However,	the	orthologs	expressed	in	airway	cells,	including	hCLCA1,	do	not	possess	this	binding	motif.	Another	domain	that	could	potentially	cause	macrophage	activation	is	the	FN3	domain	in	the	C-terminus	of	the	hCLCA1	protein.	This	FN3	domain	in	fibronectin	has	been	shown	to	induce	cytokine	expression	in	lung	fibroblasts80.	However,	increasing	the	concentration	of	the	FN3	domain	in	the	medium	by	mutating	the	hydrolase	domain	did	not	increase	macrophage	activation	(Figures	3.1).			
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3.4.4	 Pathophysiological	implications		The	signaling	ability	illustrated	by	our	findings	begins	to	explain	how	CLCA	has	such	a	pleiotropic	effect	on	airway	inflammation294.		This	effect	was	first	demonstrated	using	airway	adenoviral	gene	transfer	expressing	CLCA	in	BALB/c	mice,	in	which	the	artificial	expression	drove	and	exacerbated	mucus	production,	goblet	cell	metaplasia,	eosinophil	infiltration	and	airway	hyper-responsiveness	in	an	allergic	asthmatic	model43.	However,	subsequent	studies	in	C57BL/6	and	129v	mouse	strain	backgrounds	produced	both	conflicting	and	corroborating	results54,	99,	294,	313.	These	conflicting	studies	could	be	explained	if	CLCA	was	functioning	as	a	signaling	protein	which	modulates	a	central	mediator	of	the	immune	response	(such	as	macrophages),	which	have	a	pleiotropic	effect	on	lung	inflammation.	It	is	known	that	lung	macrophages	differ	significantly	between	mouse	strains,	and	such	variations	could	explain	the	differences	seen	in	the	CLCA	knockout	models43,	99,	294,	313,	314.																		
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3.5	 Conclusions		We	have	described	the	novel	ability	of	secreted	hCLCA1	to	function	as	a	signaling	molecule	that	can	activate	airway	macrophages.	Such	ability	likely	has	a	profound	impact	on	the	immune	response	in	the	airways,	where	the	expression	of	this	gene	is	massively	up-regulated	during	inflammation14.	Airway	macrophages	are	pivotal	regulators	of	the	inflammatory	response,	and	the	ability	of	hCLCA1	to	activate	them	could	explain	the	pleotropic	effect	seen	in	airway	inflammation	models	(where	hCLCA1	is	either	over-expressed	or	knocked	out).	The	cytokine	responses	of	the	macrophages	would	then	modify	the	inflammatory	response,	mucus	secretion,	airway	hyper-responsiveness	and	epithelial	ion-channel	function	(Figure	5.1).	Cytokines	are	known	to	modulate	these	processes315,	316.	Studies	to	identify	the	receptor	and	hCLCA1	domain	containing	the	corresponding	ligand	are	underway	but	are	beyond	the	scope	of	this	paper.	The	VWA	domain	could	be	one	potential	candidate,	where	the	same	domain	in	α2δ	subunit	binds	to	voltage-gated	calcium	channel74.	The	receptor	and	the	ligand	domain	of	hCLCA1	should	be	of	therapeutic	interest,	as	blocking	either	could	have	beneficial	effects	against	airway	inflammation.	Furthermore,	these	findings	open	a	new	area	of	investigation	into	the	function	of	CLCA	proteins.	
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Figure 3.12. Schematic model of the effects of hCLCA1 on airway macrophages. We 
hypothesized that hCLCA1 secreted from inflamed epithelial cells induces airway macrophages 
to secrete pro-inflammatory cytokines, and the cytokines will modulate different physiological 
functions including inflammation, mucus expression, ion-channel activity, and airway hyper-
responsiveness. 
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STUDY 2 – VON WILLEBRAND FACTOR TYPE A DOMAIN OF HCLCA1 IS 
RESPONSIBLE FOR MACROPHAGE ACTIVATION 
 
 
The human hCLCA1 gene is a member of CLCA gene family that has a well-documented role in 
inflammatory airway diseases. It has a pleiotropic effect on different physiological functions 
including modulation of ion-channel functions and induction of mucus production. Previously, 
we demonstrated that secreted hCLCA1 plays a role in regulating the innate immune response by 
activating airway macrophages. However, the mechanism for this regulation remains unclear. In 
this present study, we expressed recombinant proteins containing different hCLCA1 domains to 
determine the specific hCLCA1 domain(s) responsible for activation and mechanisms that are 
involved in modulating immune response in macrophage. We showed that the von Willebrand 
factor type A (VWA) domain was responsible for activating macrophages. Macrophages treated 
with VWA domain exhibited increases in both IL-1β mRNA and protein expressions which 
correlate with the activation of MAPKs and NF-κB pathways.  
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4.1 Introduction 
 
The human hCLCA1 is a member of CLCA (CL stands for chloride-channel modulating and CA 
for calcium-activated) family with a well-established role in inflammatory airway diseases such 
as asthma, cystic fibrosis and chronic obstructive pulmonary disease25, 96, 163, 186. Studies have 
reported that hCLCA1 is induced in inflamed airway epithelial cells, and this induced expression 
often exceeds that of most other inflammatory mediators14, 293. The gene products have a 
pleiotropic effect, generating secreted and membrane-associated proteins that increase mucus 
production, airway responsiveness, and increase calcium activated chloride channel 
conductance14, 21, 36, 41, 43, 85, 92, 96, 163, 293-295. Although hCLCA1 was originally identified as the 
pore subunit of the calcium activated chloride channels, we and others concluded that it is a 
chloride channel accessory protein instead1, 4, 36, 59, 60. However, how this accessory protein is 
involved in many different cellular functions remains unknown. Recently, we have identified the 
novel role of hCLCA1 as a signaling molecule45, suggesting a possible mechanism to its 
pleiotropic effect. A recent study demonstrated that secreted hCLCA1 increases the surface 
protein expression level of TMEM16A37, further supporting our proposed role of hCLCA1 as a 
signaling molecule to modulate different physiological functions. 
  
In our previous study, we have demonstrated hCLCA1 acts as a signaling molecule and 
modulates the innate immune response in macrophages45. A recent study also demonstrated that 
mCLCA3, the murine ortholog of hCLCA1, modulates leukocyte recruitment via IL-17 and 
CXCL-1 in bacterial pneumonia100, which is in line with our newly identified function of 
hCLCA1 as a modulator in immune response. However, the mechanism regarding this 
modulation remains unclear. In this study, we expressed proteins containing different hCLCA1 
domains to determine the specific hCLCA1 domain(s) and mechanisms that are involved in 
modulating the innate immune response in macrophage. From our results, we found that von 
Willebrand factor type A (VWA) domain of hCLCA1 is responsible for the up-regulation of both 
mRNA and protein expression of IL-1β. We also found that NF-κB and MAPK signaling 
pathways were activated when exposed to VWA domain, suggesting a possible mechanism of 
how hCLCA1’s VWA domain activated macrophages. 
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4.2	 Material	and	Methods		
4.2.1	 Cell	culture		Human	monocytes	(U-937	cell	line;	CRL1593.2;	ATCC)	were	grown	in	RPMI-1640	medium	(SH3025502;	Thermo	Scientific)	supplemented	with	10%	heat	inactivated	Fetal	bovine	serum	(FBS;	16000-044;	Life	Technologies)	and	1%	penicillin-streptomycin	(pen-strep;	15140-122;	Life	Technologies)	at	37	°C	in	a	humidified	atmosphere	with	5%	CO2.			
4.2.2	 Plasmid	construct		The	DNA	of	different	hCLCA1	domains	was	amplified	using	polymerase	chain	reaction	(PCR)	with	Phusion	high-fidelity	DNA	polymerase	(F531S;	Thermo	Scientific)	according	to	manufacturers’	protocols	(Table	4.1).	Hydrolase	domain	(N1-C273),	von	Willebrand	Factor	Type	A	(VWA)	domain	(N240-C544),	Hydrolase-VWA	domain	(N1-C544),	and	Fibronectin	type	III	(FN3)	domain	(N643-C915)	were	cloned	into	a	modified	pET28	HMT	vector	(containing	in	sequence,	a	hexahistidine-tag	(His6-tag),	maltose	binding	protein	(MBP),	and	a	cleavage	site	for	the	tobacco	Etch	Virus	protease	(TEV)	(Gift	of	Dr.	F.	Van	Petegem))	using	a	ligation	independent	cloning	method317.	Briefly,	pET28	HMT	vector	DNA	was	treated	with	T4	DNA	polymerase	reaction	(10	µL	DNA	(1-2	µg),	2	µL	NEBuffers	2.1,	0.5	µL	100	mM	deoxyguanosine	triphosphate	(dGTP;	N0446S;	New	England	BioLabs),	1	µL	100mM	dithiothreitol	(DTT;	BP172-5;	Fisher	Scientific),	0.4	µL	T4	DNA	polymerase	(M0203L;	New	England	BioLabs),	and	6.1	µL	H2O).	hCLCA1	domains	DNA	was	also	treated	with	T4	DNA	polymerase	reaction,	however,	deoxycytidine	triphosphate	(dCTP;	N0446S;	New	England	BioLabs)	was	used	instead	of	dGTP.	Both	vector	and	inserts	DNA	were	incubated	for	40	min	at	room	temperature	and	20	min	at	75	°C	for	heat	inactivation,	then	incubated	for	10	min	at	room	temperature	for	the	annealing	process.	The	ligation	reaction	products	were	transformed	into	Escherichia	coli	(E.	coli)	DH5α	strain	competent	cells	(18258-012;	Life	Technologies)	for	DNA	amplification.			
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For	the	transformation	process,	1-2	µL	of	ligation	reaction	products	were	added	into	100	µL	of	E.	coli	DH5α	competent	cells	and	incubated	for	30	min	on	ice	followed	by	1	min	heat	shock	at	42	°C.	Next,	1	mL	of	Luria-Bertani	(LB)	broth	(10	g/L	NaCl,	5	g/L	yeast	extract	(BP1422500;	Fisher	Scientific),	and	10	g/L	tryptone	(BP1421500;	Fisher	Scientific))	was	added	to	the	cells	and	allowed	1	h	incubation	in	a	shaking	incubator	at	37	°C.	The	cells	were	spun	down	at	3000g	for	1	min,	and	the	cell	pellets	were	plated	on	LB-agar	plate	(10	g/L	NaCl,	5	g/L	yeast	extract,	10	g/L	tryptone,	and	15	g/L	agar	(214010;	BD	Biosciences)	supplemented	with	50	µg/mL	kanamycin	for	16-18	h	at	37	°C.	Then	a	single	bacterial	colony	was	picked	and	grown	in	5	mL	LB	broth	supplemented	with	kanamycin	for	16-18	h	at	37	°C	in	a	shaking	incubator,	and	the	plasmid	DNA	was	purified	using	the	QIAprep	Spin	Miniprep	Kit	(27106;	Qiagen)	according	to	manufacturers’	protocols.	The	purified	plasmid	DNA	was	sent	for	DNA	sequencing	(Macrogen	Inc.)	to	confirm	the	presence	of	hCLCA1	domain	sequence	in	pET28	HMT	vectors	(Table	4.2).		
4.2.3	 Protein	expression,	purification,	endotoxin	removal	and	concentration	
determination		For	protein	expression,	the	plasmid	constructs	were	first	transformed	into	E.	coli	strain	Rosetta	(DE3)	competent	cells	(70954;	Novagen)	and	plated	on	LB-agar	plates	supplemented	with	50	µg/mL	kanamycin	and	35	µg/mL	chloramphenicol.	The	transformed	cells	were	grown	in	2YT	broth	(5	g/L	NaCl,	10	g/L	yeast	extract,	16	g/L	tryptone)	at	37	°C	in	a	shaking	incubator.	Cultures	were	grown	in	2YT	broth	to	an	OD600	~	0.3	at	37	°C,	and	the	temperature	was	lowered	to	18	°C.	Once	the	cultures	reached	an	OD600	~0.6-0.7,	the	cells	were	induced	with	0.2	mM	isopropyl-β-D-thiogalactoside	(IPTG;	BP16201;	Fisher	Scientific)	and	allowed	to	grow	for	a	total	of	18-22	h.			The	cultures	were	centrifuged	for	20	min	at	5000g,	and	the	cell	pellets	were	lysed	by	sonication	after	addition	of	5	mL	glycerol,	40	mL	Buffer	A	(250	mM	KCl,	10	mM	HEPES	pH	7.4)	supplemented	with	25	µg/mL	DNase	I	(D5025;	Sigma-Aldrich),	25	µg/mL	lysozyme,	1mM	phenylmethanesulfonyl	fluoride	(PMSF;	P7626;	Sigma-Aldrich)	and	10	mM	β-mercaptoethanol	(BME;	M6250;	Sigma-Aldrich).	The	lysate	was	centrifuged	for	30	min	at	
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35,000g	and	a	clarified	supernatant	was	loaded	onto	BioLogic	DuoFlow	QuadTec	40	System	(760-4137;	BioRad)	for	protein	purification.			The	proteins	were	first	purified	using	a	Profinity	IMAC	Ni-charged	resin	column	(156-0131;	BioRad).	The	proteins	were	washed	with	10	column	volumes	(CVs)	of	Buffer	A	followed	by	5	CV	of	2%	Buffer	B	(250	mM	KCl,	500	mM	imidazole	(O3196500;	Fisher	Scientific)	and	5	CV	of	4%	Buffer	B.	The	captured	proteins	were	then	eluted	by	a	gradient	of	4%-60%	Buffer	B	(up	to	300	mM	imidazole).	The	protein	elusions	were	diluted	with	an	equal	volume	of	buffer	A	and	further	purified	using	an	amylose	column	(E8021L;	New	England	BioLabs).	The	captured	proteins	were	washed	with	10	CV	of	Buffer	A	and	eluted	with	5	CV	of	Buffer	C	(250	mM	KCl,	10	mM	HEPES	pH	7.4,	and	10	mM	Maltose).	The	eluted	proteins	were	dialyzed	(211528;	Fisher	Scientific)	against	Buffer	D	(10	mM	KCl	and	20	mM	HEPES	pH	7.4)	at	4	°C	overnight	and	were	loaded	onto	a	Resource	Q	anion	exchange	column	(17-1179-01;	GE	Healthcare	Life	Sciences).	The	proteins	were	washed	with	4	CV	of	Buffer	D	and	eluted	with	a	gradient	of	0%	-	100%	Buffer	E	(1	M	KCl	and	20	mM	HEPES	pH	7.4).	The	proteins	were	concentrated	with	Amicon	ultra-15	centrifugal	filter	units	(UFC903008;	EMD	Millipore)	and	polished	by	gel-filtration	chromatography	on	a	Hiload	16/60	Superdex	200	(17-1071-01;	GE	Healthcare	Life	Sciences)	by	running	1	CV	of	Buffer	A	through	the	column	(Table	4.3).			The	eluted	proteins	were	boiled	in	2x	denaturing	buffer	(20%	glycerol,	4%	SDS,	125mM	Tris	pH	6.8,	0.3mM	bromophenol	blue)	and	10%	BME,	and	they	were	analyzed	by	12%	SDS-PAGE.	The	SDS-PAGE	gel	was	stained	with	coomassie	blue	stain	(staining	–	45%	methanol,	10%	glacial	acetic	acid,	45%	water,	3	g/L	Coomassie	Brilliant	Blue	R250;	destaining	–	20%	methanol,	10%	glacial	acetic	acid,	70%	water).	After	confirming	the	purity	of	the	eluted	proteins,	they	were	concentrated	to	a	final	volume	of	~1.5	mL,	and	were	subjected	to	endotoxin	removal	assay	using	Triton-X114	phase	separation	technique.	The	purified	proteins	were	treated	with	1%	triton-X114,	incubated	for	20	min	at	4	°C,	10	min	at	37	°C,	and	centrifugation	for	10	min	at	20,000g.	This	process	was	repeated	3x	to	completely	remove	endotoxin	residuals	from	the	proteins.	The	endotoxin	level	was	validated	using	GenScript	ToxinSensor	chromogenic	LAL	endotoxin	assay	kit	(L00350;	GenScript)	to	ensure	
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the	endotoxin	level	is	below	0.01	EU/mL.	The	protein	concentration	of	the	purified	proteins	was	determined	using	Pierce	BCA	protein	assay	kit	(23225;	Thermo	Scientific)	according	to	the	manufacturers’	protocols.			
4.2.4	 Monocyte	differentiation	and	activation		Monocyte	cells	were	seeded	in	each	well	(1.3×106	to	1.5×106	cells/well)	in	a	6-well	plate	and	differentiated	into	macrophages	with	0.1	nM	phorbol-12-myristate-13-acetate	(PMA;	P8139;	Sigma-Aldrich)	in	supplemented	FBS-free	RPMI-1640	medium	for	18	h.	The	cells	were	washed	2	times	with	FBS-free	RPMI-1640	medium	and	incubated	in	supplemented	RPMI-1640	medium	containing	6%	FBS.	For	the	IL-1β	experiment,	1	μg/mL	or	5	μg/mL	of	different	purified	hCLCA1	domain	proteins	were	added	to	macrophages	for	48	h.	For	the	cell	signaling	experiment,	5	μg	of	HMT	or	VWA	proteins	were	added	to	macrophages	for	2,	4,	6,	or	12	h.			
4.2.5	 RNA	isolation	and	real-time	quantitative	PCR		RNA	was	extracted	using	TRIzol	reagent	(15596018;	Life	Technologies)	according	to	manufacturers’	protocols.	The	collected	RNA	was	analyzed	with	a	GoTaq	2-Step	RT-qPCR	system	(A6010;	Promega)	and	Mx3005P	real-time	PCR	machine	(401514;	Agilent).	cDNA	of	each	sample	was	measured	in	duplicates	in	Mx3005P	real-time	qPCR	machine,	and	the	average	CT	(cycle	threshold)	value	was	used	to	calculate	the	fold	difference	of	each	gene.	Primers	were	designed	for	GAPDH,	TNF-α,	IL-12a,	IL-8,	IL-1β,	IL-6	and	IL-10	(Table	4.4).		
4.2.6	 Efficiency	and	fold	difference	calculations		Dilution	series	from	1×100-fold	to	1×10−5-fold	of	cDNA	were	used	to	determine	the	primer	efficiency.	The	CT	value	obtained	in	each	dilution	was	used	to	generate	a	linear	plot	of	CT	vs.	log	copies.	The	efficiency	of	the	primer	set	was	determined	with	the	equation	Eff	=	10(−1/slope).	The	fold	difference	between	hCLCA1’s	domains-activated	and	unstimulated	
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samples	was	determined	using	an	efficiency-corrected	calculation	with	unstimulated	macrophage	serving	as	control	and	GAPDH	serving	as	the	reference	gene304:		 		
4.2.7	 SDS-PAGE	and	western	blot	Analysis		For	IL-1β	experiments,	cell	lysates	were	collected	using	M-PER	mammalian	protein	extraction	reagent	(78503;	Thermo	Scientific)	with	the	addition	of	Halt	protease	and	phosphatase	inhibitor	cocktail	(78440;	Thermo	Scientific).	Cell	lysates	were	resolved	by	12%	SDS-PAGE	and	electroblotted	onto	PVDF	membrane.	Membranes	were	blocked	with	Amresco	rapidblock	blocking	solution	(M325;	Amresco)	for	1	h	at	room	temperature.	The	membranes	were	subsequently	probed	overnight	at	4	°C	with	primary	antibodies	in	rapidblock	blocking	solution.	The	membranes	were	then	incubated	1	h	at	room	temperature	with	secondary	antibodies	in	rapidblock	blocking	solution.	The	primary	antibodies	used	were	GAPDH	(MAB374;	EMD	Millipore)	and	IL-1β	(H-153;	sc-7884;	Santa	Cruz),	and	the	secondary	antibodies	used	were	DyLight	488	conjugate	Goat	anti-Rabbit	IgG	antibody	(35552;	Thermo	Scientific)	and	ECL	Plex	Goat	anti-Mouse	IgG-Cy5	antibody	(PA45009;	Amersham	Biosciences).	Proteins	were	detected	and	analyzed	using	Typhoon	Trio	and	ImageQuant	TL	system	(63005583;	GE	healthcare	Life	Sciences).	Densitometry	analysis	of	intracellular	IL-1β	protein	was	normalized	to	GAPDH	in	each	sample.	For	cell	signaling	experiments,	stimulated	macrophages	were	extracted	using	Pierce	NE-PER	nuclear	and	cytoplasmic	extraction	kit	(78833;	Pierce)	with	the	addition	of	Halt	protease	and	phosphatase	inhibitor	cocktail.	The	nuclear	fractions	were	then	resolved	by	12%	SDS-PAGE	and	electroblotted	onto	PVDF	membrane.	Membranes	were	blocked	with	Pierce	protein-free	(TBS)	blocking	buffer	(37570;	Pierce)	for	1	h	at	room	temperature.	The	membranes	were	probed	with	primary	cell	signaling	antibodies	for	3	h	at	room	temperature	and	with	secondary	antibodies	for	1.5	h	at	room	temperature.	Then	the	proteins	were	detected	immediately.	After	protein	detection,	the	antibodies	were	removed	from	membrane	by	incubating	with	Amresco	gentle	review	stripping	buffer	(N552;	Amresco)	for	30	min	at	room	temperature,	and	the	membranes	were	probed	against	
( ) ( ) ( ) ( )T, target T, refMean control  Mean sample Mean control  Mean sampletarget ref/
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primary	β-actin	antibody	(C-4;	sc-47778;	Santa	Cruz)	overnight	at	4	°C.	The	membranes	were	then	incubated	with	secondary	antibodies	for	1	h	at	room	temperature.	Proteins	were	detected	and	analyzed	using	Typhoon	Trio	and	ImageQuant	TL	system.	Densitometry	analysis	of	phosphorylated	proteins	was	normalized	to	β-actin	in	each	sample.	The	primary	antibodies	used	were	phospho-p44/42	MAPK	(Thr202/Tyr204)	(4377S;	Cell	Signaling	Technology),	phospho-p38	MAPK	(Thr180/Tyr182)	(4511S;	Cell	Signaling	Technology),	phospho-SAPK/JNK	(Thr183/Tyr185)	(9251S;	Cell	Signaling	Technology),	and	phospho-IKappaB-alpha	(Ser32)	(2859S;	Cell	Signaling	Technology).	The	secondary	antibodies	used	were	DyLight	488	conjugate	Goat	anti-Rabbit	IgG	antibody	and	ECL	Plex	Goat	anti-Mouse	IgG-Cy5	antibody.			
4.2.8	 Statistics		All	data	are	expressed	as	means	±	standard	error	of	the	mean	(SEM).	Each	biological	replicate	was	a	result	of	an	individual	activation	paired	with	a	control.	Each	biological	replicate	was	performed	on	different	days.	Fold	differences	were	calculated	by	comparing	hCLCA1’s	domains-activated	macrophage	to	its	paired	macrophage	control.	The	normality	and	variance	tests	were	done	using	Shaprio-Wilk	test	and	Levene’s	test	respectively,	and	the	fold	difference	values	of	RT-qPCR	and	IL-1β	western	blot	densitometry	were	analyzed	using	ANOVA	following	Tukey’s	Honestly-Significant-Difference	Test306.	For	cell	signaling	western	blot	densitometry,	the	fold	differences	values	were	analyzed	using	Kruskal-Wallis	one-way	analysis	of	variance	test	with	Conover-Inman	test.	All	western	blot	data	was	normalized	to	the	appropriate	controls,	and	each	western	blot	was	a	result	of	an	individual	biological	replicate.	Significance	was	determined	at	p	<	0.05.			
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Table 4.1. Primers used for cloning. 
Human CLCA1 PCR Primers for cloning 
Primer Name Primer Sequence (5′ à  3′) 
TAC TTC CAA TCC AAT GCA ATG GGC CCC TTC AAG 
TAC TTC CAA TCC AAT GCA GCC CAG CAC GTG GAC 
TAC TTC CAA TCC AAT GCA CTG GAC AAT GGA GCC 
TTA TCC ACT TCC AAT GGC CTA CTT ATC GAC CAC AAA 
TTA TCC ACT TCC AAT GGC TCA GGC GAT ACT CAG 
F.P. LIC-N1-hCLCA1 
F.P. LIC-N240-hCLCA1 
F.P. LIC-N643-hCLCA1 
R.P. LIC-C544-hCLCA1 
R.P. LIC-C915-hCLCA1 
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Table 4.2. Primers used for sequencing. 
Human CLCA1 PCR Primers for sequencing 
Primer Name Primer Sequence (5′ à  3′) 
ATA TAA AAA TGC AGA CGT GCT GGT CGC CGA AA 
GCA GAG TAT GGG CCC CAG GGC CGA GCT TTT G  
CTT CAG CCT GCT GCA GAT CGG GCA GCG GAT C 
GGC ACA GTG ATC GTC GAC TCA ACT GTG GGA  
GGG TCC TTT GTG GCT TCT GAC GTG CCA AAC GC 
F.P. 306-hCLCA1 
R.P. 475-hCLCA1 
F.P. 900-hCLCA1 
F.P. 1522-hCLCA1 
F.P. 2215-hCLCA1 
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Table 4.3. Purification protocols for different constructs. 
Construct name Purification protocol 
HMT Ni2+ charged resin column à Amylose 
column à Dialyzed overnight with buffer 
D à anion exchange column 
Hydrolase domain (N1-C273) Ni2+ charged resin column à Amylose 
column à Dialyzed overnight with buffer 
D à anion exchange column à Size 
exclusion chromatography column 
Hydrolase-VWA domain (N1-C544) Ni2+ charged resin column à Amylose 
column à Dialyzed overnight with buffer 
D à anion exchange column à Size 
exclusion chromatography column 
VWA domain (N240-C544) Ni2+ charged resin column à Amylose 
column à Size exclusion chromatography 
column 
FN3 domain (N643-C915) Ni2+ charged resin column à Amylose 
column à Dialyzed overnight with buffer 
D à anion exchange column à Size 
exclusion chromatography column 
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Table 4.4. Primers used in RT-qPCR experiments. 
Human qPCR Primers 
Gene 
Name 
 
Forward Primers (5′ à  3′) 
 
Reverse Primers (5′ à  3′) 
GAPDH CAAGGTCATCCATGACAACTTTG GGGCCATCCACAGTCTTCTG 
TNF-α TGCTGCACTTTGGAGTGATCG TGCTACAACATGGGCTACAGG 
IL-12a CAGTGGAGGCCTGTTTACCATTG TACTACTAAGGCACAGGGCCATC 
IL-8 TCTCTTGGCAGCCTTCCTGATTTC ATTTCTGTGTTGGCGCAGTGTG 
IL-1β GCTGATGGCCCTAAACAGATG TGTAGTGGTGGTCGGAGATTC 
IL-6 AGCCACTCACCTCTTCAGAAC GTGCCTCTTTGCTGCTTTCAC 
IL-10 AAGCTGAGAACCAAGACCCAGACA AAAGGCATTCTTCACCTGCTCCAC 
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4.3	 Results	
	
4.3.1	 Purification	of	hCLCA1	domain	proteins	
	DNAs	of	different	hCLCA1	domains	were	subcloned	into	a	pET28	HMT	vector:	hydrolase	domain	(N1-C273),	von	Willebrand	factor	type	A	(VWA)	domain	(N240-C544),	hydrolase-VWA	domain	(N1-C544),	and	fibronectin	type	III	(FN3)	domain	(N643-C915)	(Figure	4.1),	and	each	of	the	clones	contains	a	hexahistidine-tag	(His6-tag)	and	a	maltose	binding	protein	(MBP)	at	the	N-terminal	end	of	the	sequence.	The	sequences	of	the	clones	were	confirmed	prior	to	expression	and	purification	using	fast	protein	liquid	chromatography	with	the	following	purification	columns:	Ni2+-charged	resin	column,	amylose	column,	anion	exchange	column,	and	size	exclusion	chromatography	column	(Table	4.2).	The	eluted	proteins	were	analyzed	by	coomassie	stained	gel	and	the	fractions	containing	the	desired	proteins	were	further	polished	by	endotoxin	removal	procedures	(Figure	4.2).	After	that,	the	purity	of	the	proteins	was	confirmed	by	coomassie	stained	gel	(Figure	4.3).		
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Figure 4.1. hCLCA1 domain DNA constructs design. Four DNA constructs were designed to 
capture different domains of hCLCA1: N1-C273 contains the hydrolase domain, N1-C544 
contains the hydrolase and VWA domain, N240-C544 contains the VWA domain, and N643-
C915 contains the FN3 domain.  
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Figure 4.2. Representative coomassie stained gel showing the purification process of a 
recombinant protein. The recombinant protein (VWA domain in this case) was initially purified 
with a nickel column, followed by an amylose column and a size exclusion chromatography 
column. Only the fractions containing pure protein (fraction # 1-6) from size exclusion 
chromatography column were collected for subsequent experiments. 
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Figure 4.3. Representative coomassie stained gel showing the purity of different hCLCA1 
domain proteins. Different recombinant proteins were expressed and purified, and subsequently 
analyzed on a coomassie stained gel. The recombinant proteins were loaded from left to right: 
HMT vector (negative control), hydrolase domain (N1-C273), hydrolase-VWA domain (N1-
C544), VWA domain (N240-C544), and FN3 domain (N643-C915). 
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4.3.2	 Activation	of	the	U-937	macrophages	with	hCLCA1	domains		Activation	of	macrophages	by	hCLCA1	domains	was	investigated	using	the	U-937	macrophage	cell	line	treated	with	5	μg/mL	of	purified	hCLCA1	domain	proteins	for	48	h.	Macrophage	activation	was	assessed	by	expression	of	the	pro-inflammatory	cytokines	TNF-α,	IL-8,	IL-1β,	IL-6,	and	IL-10.	The	mRNA	expression	of	IL-1β	in	VWA-treated	macrophages	had	a	2.08±0.19	fold	increase	over	the	control	(Figure	4.4).	The	IL-1β	mRNA	expression	in	VWA-treated	macrophages	was	also	significantly	over	the	HMT-treated	macrophages.	HMT	protein	was	used	as	an	additional	control	because	all	purified	hCLCA1’s	domain	proteins	contain	a	His6-tag	and	a	MBP	at	the	N-terminal	end	of	the	sequence.	Beside	VWA	domain,	none	of	the	other	hCLCA1’s	domain	proteins	elicit	any	pro-inflammatory	response	in	macrophages.			The	increase	in	IL-1β	mRNA	expression	was	translated	into	an	elevated	IL-1β	protein	levels.	Western	blot	and	densitometry	analysis	showed	that	VWA-treated	macrophages	had	a	2.38±0.18	fold	increase	in	IL-1β	protein	expression	over	the	control	(Figure	4.5).	Also,	the	IL-1β	protein	expression	of	VWA-treated	macrophages	was	also	significantly	increased	over	the	HMT-treated	macrophages.	Similar	to	the	mRNA	experiment,	none	of	the	other	hCLCA1’s	domain	proteins	induce	IL-1β	protein	expression	compared	to	the	control.	
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Figure 4.4. Effect on cytokine expression of macrophages exposed to 5 µg/mL purified 
hCLCA1 domains. U-937 macrophages were treated for 48 h using 5 µg/mL of different 
purified hCLCA1 domain proteins. TNF-α, IL-8, IL-1β, IL-6, and IL-10 were quantified by their 
mRNA expression using RT-qPCR. N240-C544 (VWA domain) has a 2.08 ± 0.19 fold increase 
over the control in IL-1β mRNA expression level. The fold difference of each sample was 
compared against the control. Results were the means of 5 samples ± SEM. Significant fold 
differences from corresponding control values are indicated by * (p < 0.05), ** (p < 0.005) and 
*** (p < 0.001). 
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Figure 4.5. VWA domain (N240-C544) of hCLCA1 increased IL-1β protein expression 
level. U-937 macrophages were treated for 48 h using 5 µg/mL of different purified hCLCA1 
domain proteins. Western blot and densitometry showed that 5 µg/mL VWA domain treatments 
induced a 2.38 ± 0.18 folds increase in IL-1β protein expression, while other hCLCA1 domains 
treatment showed no effect. The fold difference of each sample was compared against the 
control. Results were the means of 3 samples ± SEM. Significant fold differences from 
corresponding control values are indicated by * (p < 0.05), ** (p < 0.005) and *** (p < 0.001). 
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4.3.3 Phosphorylation of MAPKs and NF-κB pathways by VWA domain 
To determine the signal transduction pathway by which VWA domain is involved in this 
induction, macrophages were treated with 5 µg/mL HMT protein or VWA domain protein for 2, 
4, 6, or 12 h. Nuclear fraction proteins were extracted and analyzed using western blot against 
phospho-specific antibodies involved in MAPK and NF-κB pathway. MAPK pathway was tested 
with p-p38, p-ERK, and p-JNK antibodies, while NF-κB pathway was tested with p-IκB-α 
antibody. To validate each antibody, western blot was performed on nuclear fraction proteins 
extracted from LPS-induced macrophages (Figure 4.6).  
Western blot and densitometry analysis showed that VWA domain significantly induced the 
phosphorylation of IκB-α (Figure 4.7), p38 (Figure 4.8), and ERK (Figure 4.9) in macrophages 
over the HMT protein-activated macrophages, while JNK was neither detected in HMT-treated 
nor VWA-treated macrophages (data not shown). Generally, increased phosphorylation was 
observed with increased incubation duration of VWA domain, this indicates a potential positive 
feedback mechanism was involved to perpetuate the inflammatory phenotype of macrophages. 
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Figure 4.6. Validation of phosphor-specific antibodies with LPS-induced macrophages. 
Macrophages were activated with 1 µg/mL LPS for 4 h before protein isolation. Nuclear fraction 
proteins were analyzed with western blot against different phosphor-specific antibodies: p-IκB-α, 
p-p38, p-ERK, and p-JNK. Following LPS induction, the phosphorylated proteins were 
successfully detected by the phosphor-specific antibodies. 
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Figure 4.7. Phosphorylation of IκB-α with VWA domain treatment. U-937 macrophages 
were treated for 2, 4, 6, or 12 h with 5 µg/mL of HMT protein or VWA domain protein. Western 
blot and densitometry showed that VWA domain significantly induced the phosphorylation of 
IκB-α. The fold difference of each sample was compared against HMT-treated macrophage at 1 
h. Results were the means of 3 samples ± SEM. Significant fold differences from corresponding 
control values are indicated by * (p < 0.05), ** (p < 0.005) and *** (p < 0.001). 
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Figure 4.8. Phosphorylation of p38 with VWA domain treatment. U-937 macrophages were 
treated for 2, 4, 6, or 12 h with 5 µg/mL of HMT protein or VWA domain protein. Western blot 
and densitometry showed that VWA domain significantly induced the phosphorylation of p38. 
The fold difference of each sample was compared against HMT-treated macrophage at 1 h. 
Results were the means of 3 samples ± SEM. Significant fold differences from corresponding 
control values are indicated by * (p < 0.05), ** (p < 0.005) and *** (p < 0.001). 
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Figure 4.9. Phosphorylation of ERK with VWA domain treatment. U-937 macrophages were 
treated for 2, 4, 6, or 12 h with 5 µg/mL of HMT protein or VWA domain protein. Western blot 
and densitometry showed that VWA domain significantly induced the phosphorylation of ERK. 
The fold difference of each sample was compared against HMT-treated macrophage at 1 h. 
Results were the means of 3 samples ± SEM. Significant fold differences from corresponding 
control values are indicated by * (p < 0.05), ** (p < 0.005) and *** (p < 0.001). 
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4.4	 Discussion		In	our	previous	study,	we	have	demonstrated	that	secreted	hCLCA1	has	the	capability	to	induce	pro-inflammatory	cytokines	in	macrophages45.	Recent	studies	have	further	support	our	proposed	novel	function	of	hCLCA1	as	a	signaling	molecule37,	41,	100.	In	the	present	study,	we	identified	the	functional	domain	of	hCLCA1	responsible	for	macrophage	activation,	and	we	also	described	a	signal	transduction	pathway	involved	in	this	activation.	The	results	demonstrate	that	the	von	Willebrand	factor	type	A	domain	of	hCLCA1	is	responsible	for	IL-1β	induction	in	macrophages,	and	this	induction	correlated	with	the	activation	of	NF-κB	and	MAPK	signaling	pathway.			
4.4.1	 Purification	of	hCLCA1	domain	proteins		Initially,	we	subcloned	different	segments	of	the	hCLCA1	gene	into	the	HMT	vector.	HMT	vector	was	chosen	because	the	expressed	fusion	protein	will	contain	a	His6-tag	and	a	MBP	at	the	N-terminus	of	the	protein,	which	will	allow	for	protein	purification	using	fast	protein	liquid	chromatography.	MBP	is	thought	to	act	as	a	general	molecular	chaperone	to	assist	protein	folding318,	319.	This	was	confirmed	as	we	observed	protein	degradation	of	hydrolase	domain	protein	(N1-C273)	after	we	cleaved	and	removed	the	protein	tags	using	tobacco	Etch	Virus	(TEV)	protease.	Although	previous	studies	have	reported	that	MBP-tag	in	fusion	protein	does	not	reduce	bioactivity320,	321,	we	cannot	exclude	the	possibility	that	it	might	create	conformation	hindrance	on	the	binding	site	of	the	protein.	After	proteins	were	purified,	endotoxin	was	removed	from	the	proteins	using	a	Triton	X-114	phase	separation	technique.	Using	Triton	X-114,	Adam	et	al.	showed	a	100-fold	endotoxin	reduction	in	2	steps,	however,	50%	loss	in	bioactivity	of	the	protein	was	also	observed322.	In	our	experiment,	a	3-step	protocol	was	required	to	reduce	the	endotoxin	level	below	0.01	EU/mL,	which	potentially	results	in	a	greater	loss	of	bioactivity	in	the	protein.	Our	results	demonstrated	that	the	activation	of	macrophages	was	solely	due	to	the	VWA	domain	and	not	to	LPS	contamination	because	phosphorylation	was	observed	only	in	ERK,	p38,	NF-κB,	but	not	JNK.	On	the	other	hand,	phosphorylation	of	ERK,	p38,	JNK,	and	NF-κB	was	observed	in	LPS-induced	macrophages	(Figure	4.6).		
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4.4.2	 Macrophage	activation	by	von	Willebrand	factor	type	A	domain		hCLCA1	domain	proteins	were	used	to	activate	U-937	macrophages.	A	preliminary	concentration	response	experiment	was	initially	performed	in	which	macrophages	were	treated	with	1	μg/mL	or	5	μg/mL	of	proteins.	However,	only	5	μg/mL	proteins	were	able	to	induce	inflammatory	response.	In	our	previous	study,	~150	pg/mL	of	immuno-purified	hCLCA1	was	sufficient	to	induce	macrophage	activation,	while	another	study	reported	the	physiological	concentration	of	hCLCA1	in	IL-13-induced	NHBE	cells	was	~0.23	μg/mL41.	A	seemingly	high	dose	of	hCLCA1	domain	proteins	required	for	macrophage	activation	in	this	study	might	possibly	be	attributed	to	reduced	bioactivity	of	the	proteins.	As	mentioned	above,	the	conformation	hindrance	imposed	by	the	MBP	tag	and	treatment	with	Triton-X114	could	drastically	reduce	the	bioactivity	of	the	proteins.	In	addition,	secreted	hCLCA1	has	been	shown	to	be	a	highly	glycosylated	protein7,	21,	and	glycosylation	is	known	to	modulate	the	structure	and	function	of	signaling	molecules65-67.	The	lack	of	glycosylation	on	hCLCA1	domain	proteins	using	the	E.	coli	expression	system	might	have	a	detrimental	effect	on	its	bioactivity.	Together,	a	dramatically	reduced	bioactivity	might	be	explained,	thus	providing	a	possible	explanation	for	the	high	concentration	of	proteins	required	to	activate	macrophages.			Of	all	the	protein	constructs	tested	(HMT,	hydrolase	domain,	hydrolase-VWA	domain,	VWA	and	FN3	domain),	only	VWA	domain	protein	elicited	an	inflammatory	response	in	macrophages,	and	the	response	was	limited	to	IL-1β	(Figure	4.4).	Western	blot	and	densitometry	analysis	showed	that	the	increase	in	IL-1β	mRNA	expression	was	translated	into	an	elevated	protein	level	(Figure	4.5).	This	result	coincides	with	our	previous	findings,	in	which	IL-1β	was	the	most	induced	cytokine	activated	by	immuno-purified	hCLCA1	(Figure	3.11)45.	It	is	important	to	note	that	although	hydrolase-VWA	domain	did	not	induce	any	significant	inflammatory	response,	it	did	induce	the	second	highest	IL-1β	and	IL-8	mRNA	expression	(Figure	4.4).	This	might	be	attributed	to	the	structural	conformation	of	the	protein	that	prevents	the	accessibility	of	binding	site	for	protein	interaction.		The	VWA	domain	is	a	well-studied	domain	involved	in	cell	adhesion,	in	extracellular	matrix	proteins,	and	in	integrin	receptors71-73.	The	VWA	domain	of	hCLCA1	contains	three	metal-
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ion-dependent	adhesion	site	(MIDAS)	motifs.	Previous	studies	have	demonstrated	that	the	MIDAS	motif	in	the	α2δ	subunit	of	the	voltage	gated	calcium	channel	is	essential	for	its	function	in	calcium	channel	trafficking	and	modulation74-77.	A	recent	study	has	demonstrated	that	secreted	hCLCA1	increased	calcium-activated	chloride	channel	conductance37,	similar	to	how	the	α2δ	subunit	of	the	voltage	gated	calcium	channel	modulates	its	function74.	From	these	studies,	it	is	possible	that	the	MIDAS	motifs	in	hCLCA1’s	VWA	domain	are	the	active	sites	that	are	responsible	for	macrophage	activation.		
4.4.3	 Activation	of	MAPKs	and	NF-κB	pathways	by	VWA	domain	
	To	investigate	the	cell	signaling	pathway	which	VWA	induced	in	macrophages,	we	performed	western	blot	for	selected	phospho-specific	proteins	involved	in	NF-κB	and	MAPK.	These	two	pathways	were	chosen	because	activation	of	these	pathways	result	in	IL-1β	expression234,	323-326.	From	our	western	blot	analysis,	we	observed	an	increase	in	phosphorylation	of	IκB-α,	p38	and	ERK	with	VWA	domain	incubation	(Figure	4.7,	Figure	4.8,	and	Figure	4.9).	However,	phosphorylation	of	JNK	was	not	observed	with	VWA	domain	incubation.		It	has	been	well	documented	that	both	activation	of	NF-κB	pathway	and	phosphorylation	of	ERK	result	in	IL-1β	expression234,	252,	326,	327,	and	phosphorylation	of	p38	contributes	to	the	activation	of	NF-κB	pathway328-330.	Interestingly,	one	group	has	reported	that	phosphorylation	of	p38	activates	the	NF-κB	pathway,	resulting	in	an	up-regulation	of	macrophage	inflammatory	protein	1α	(MIP-1α),	a	chemokine	for	macrophage	recruitment331.	These	studies,	together	with	our	findings,	partly	explain	how	hCLCA1	modulates	macrophage	function.	Secreted	hCLCA1	interacts	with	macrophages,	activating	both	ERK	and	p38.	Phosphorylation	of	p38	subsequently	activates	NF-κB	pathway	and	induces	MIP-1α	expression,	recruiting	more	macrophages	to	the	site	of	inflammation.	This	creates	a	positive	feedback	system	in	which	more	macrophages	are	available	for	hCLCA1	to	interact	with.	Then,	activation	of	NF-κB	pathway	and	phosphorylation	of	ERK	together,	induce	IL-1β	expression	in	macrophages,	thus	enhancing	the	inflammatory	response	(Figure	4.10).		
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Figure 4.10. Schematic model of how hCLCA1 induces inflammatory response in airway 
macrophages. We hypothesized that hCLCA1 secreted from inflamed epithelial cells activates 
macrophages via the activation of ERK and p38, in which p38 activation leads to activation of 
NF-κB, and together they induce IL-1β expression. In addition, activation of NF-κB by p38 also 
increases the expression of MIP-1α, which recruits additional macrophages to the site of 
inflammation to perpetuate the innate immune response.  
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4.5	 Conclusions		In	our	previous	study,	we	have	described	the	novel	ability	of	secreted	hCLCA1	to	function	as	a	signaling	molecule	that	can	activate	airway	macrophages45.	Such	ability	likely	has	a	profound	impact	on	the	immune	response	in	the	airways,	where	the	expression	of	this	gene	is	massively	up-regulated	during	inflammation14.	In	the	present	study,	we	have	identified	the	VWA	domain	of	hCLCA1	as	the	one	responsible	for	macrophage	activation,	and	this	correlates	with	the	activation	of	NF-κB	and	MAPK	pathways.	These	pathways	lead	to	an	increase	in	inflammatory	cytokines	expression.	The	cytokine	response	of	the	macrophages	would	then	modify	the	inflammatory	response,	mucus	secretion,	and	airway	responsiveness	in	airway	diseases.	Studies	to	identify	the	receptor	will	be	of	great	therapeutic	interest	because	it	will	provide	new	way	to	reduce	the	severity	of	airway	inflammation,	but	it	is	beyond	the	scope	of	this	paper.					
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GENERAL	DISCUSSION		
5.1	 Implication		Airway	diseases	such	as	asthma,	cystic	fibrosis,	or	chronic	obstructive	pulmonary	diseases	are	one	of	the	leading	causes	of	morbidity	and	mortality	worldwide.	Patients	suffering	from	these	airway	diseases	often	suffer	from	chronic	inflammation,	mucus	hypersecretion,	airflow	obstruction,	and	even	respiration	failure	or	death	during	disease	exacerbation.		During	airway	inflammation,	inflamed	epithelial	cells	secrete	increased	levels	of	cytokines	and	chemokines	to	initiate	the	innate	immune	response.	These	molecules	recruit	inflammatory	cells	to	the	site	of	inflammation,	and	these	inflammatory	cells	secrete	additional	inflammatory	mediators	to	amplify	the	immune	response.	Although	these	immune	responses	are	important	to	protect	the	host	against	pathogens,	failure	to	resolve	inflammation	brings	forth	a	detrimental	effect.	These	are	salient	in	the	cases	of	COPD	and	asthma,	in	which	persisted	inflamed	airways	lead	to	chronic	bronchitis,	emphysema,	airway	remodeling,	and	severe	airway	constriction.			Beside	inflammatory	mediators	such	as	cytokines	and	chemokines,	hCLCA1	is	one	of	the	most	induced	proteins	expressed	in	inflamed	airways.	It	has	a	well-documented	involvement	in	goblet	cell	metaplasia	in	patients	suffering	from	these	airway	diseases.	However,	its	role	in	inflammation	has	remained	unknown.	In	our	studies,	we	demonstrated	that	hCLCA1	has	the	ability	to	modulate	the	immune	response	in	airway	macrophages.	We	showed	that	secreted	hCLCA1	could	act	as	a	signaling	molecule	to	induce	inflammatory	response	both	in	U-937	macrophage	cell	line	and	in	primary	porcine	alveolar	macrophages.	Furthermore,	we	have	identified	VWA	domain	of	hCLCA1	as	the	functional	domain	responsible	for	macrophage	activation,	and	it	is	via	activation	of	NF-κB	and	MAPK	pathway.	Our	findings	suggest	that	hCLCA1	has	the	potential	to	amplify	the	inflammatory	response	in	macrophages,	and	this	might	contribute	to	the	tissue	damages	associated	with	airway	diseases.		
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Therefore,	understanding	the	functional	domain	and	mechanism	can	provide	directions	on	novel	treatment	to	control	inflammation	triggered	by	macrophages	in	airway	disease	patients,	thus	minimizing	the	severity	of	the	diseases.	It	is	also	of	great	therapeutic	interest	because	it	provides	a	non-steroidal	anti-inflammatory	drugs	alternative,	thus	eliminating	possible	side	effects	such	as	weight	gain,	insomnia,	osteoporosis,	etc.																											
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5.2	 Future	Research		In	our	studies,	we	have	identified	the	VWA	domain	of	hCLCA1	to	be	responsible	for	macrophage	activation.	However,	the	key	amino	acid	residues	involved	in	this	interaction	remains	unknown.	Therefore,	a	mutation	study	should	be	carried	out	to	identify	the	specific	amino	acid	residues.	Specific	amino	acid	residues	within	the	VWA	domain	determined	by	proteomic	bioinformatics	tools	will	be	mutated	into	alanine	through	site-directed	mutagenesis.	The	mutated	proteins	will	be	added	to	the	macrophage	to	determine	which	mutations	can	attenuate	macrophage	activation.	This	information	will	be	vital	to	hCLCA1	inhibitor	design	to	ameliorate	the	severity	of	airway	inflammation.		We	would	also	like	to	identify	the	binding	partners	of	hCLCA1	through	polyHis-tagged	pull	down	assay.	HMT-fused	VWA	domain	protein	will	be	immobilized	on	a	nickel	column,	and	macrophage	cell	lysate	will	be	loaded	onto	the	column	for	pull-down	assay.	The	interaction	complex	will	be	eluted	and	analyzed	with	western	blot	and	mass	spectrometry.	If	the	interaction	between	hCLCA1	and	its	binding	partner	is	weak,	a	crosslinking	assay	will	be	used	instead.	To	confirm	that	the	binding	ligand	discovered	is	responsible	for	macrophage	activation,	heterozygous	dominant	negative	constructs	of	the	ligand	will	be	synthesized	and	added	to	the	macrophage,	followed	by	hCLCA1	activation.	Then	RT-qPCR	or	western	blot	will	be	used	to	evaluate	cytokine	expression.			In	our	second	study,	we	proposed	a	possible	mechanism	by	which	hCLCA1	modulates	the	inflammatory	response	in	macrophages	through	activation	of	the	ERK	and	p38-dependent	NF-κB	pathways.	To	confirm	this,	a	temporal	experiment	should	be	carried	out	using	inhibitors	targeting	the	ERK	and	p38	pathway,	follow	by	western	blot	against	IL-1β	or	IκB-α.	This	will	allow	us	to	definitively	show	which	cell	signaling	pathway	hCLCA1	initially	triggers,	and	whether	such	cell	signaling	pathway	result	in	inflammatory	response	in	macrophages.		
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